ANNEXES2016

1ER CENTRE DE LUTTE CONTRE LE CANCER EN EUROPE

L E A D E R S

1. Al Nakouzi N., Wang C.K., Beraldi E., Jager W., Ettinger S., Fazli L., Nappi L., Bishop J., Zhang F., Chauchereau A., Loriot Y., and Gleave M. Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis. [2016] EMBO Molecular Medi-cine (8) 7 : 761-778.

2. Alsafadi S., Tourpin S., Bessoltane N., Salome-Desnoulez S., Vassal G., Andre F., and Aho-madegbe J.C. Nuclear localization of the caspase-3-cleaved form of p73 in anoikis. [2016] Oncotarget (7) 11 : 12331-12343.

3. Anantharaman D., Muller D.C., Lagiou P., Ahrens W., Holcatova I., Merletti F., Kjaerheim K., Polesel J., Simonato L., Canova C., Castellsague X., Mac-farlane T.V., Znaor A., Thomson P., Robinson M., Conway D.I., Healy C.M., Tjonneland A., Westin U., Ekstrom J., Chang-Claude J., Kaaks R., Overvad K., Drogan D., Hallmans G., Laurell G., Bueno-De-Mes-quita H.B., Peeters P.H., Agudo A., Larranaga N., Travis R.C., Palli D., Barricarte A., Trichopoulou A., George S., Trichopoulos D., Quiros J.R., Grioni S., Sacerdote C., Navarro C., Sanchez M.J., Tumino R., Severi G., Boutron-Ruault M.C., Clavel-Chape-lon F., Panico S., Weiderpass E., Lund E., Gram I.T., Riboli E., Pawlita M., Waterboer T., Kreimer A.R., Johansson M., and Brennan P. Combined effects of smoking and HPV16 in oropharyngeal cancer. [2016] International Journal of Epidemiology (45) 3 : 752-761.

4. Anderson M., Sansonetti P.J., and Marteyn B.S. Shigella Diversity and Changing Landscape: Insights for the Twenty-First Century. [2016] Frontiers in Cellu-lar and Infection Microbiology (6) : 45.

5. Angileri F., Morrow G., Scoazec J.Y., Gadot N., Roy V., Huang S., Wu T., and Tanguay R.M. Identification of circulating microRNAs during the liver neoplastic process in a murine model of hereditary tyrosinemia type 1. [2016] Scientific Reports (6) : 27464.

6. Apcher S., Prado Martins R., and Fahraeus R. The source of MHC class I presented peptides and its implications. [2016] Current Opinion in Immunology (40) : 117-122.

7. Aspeslagh S., Postel-Vinay S., Rusakiewicz S., Soria J.C., Zitvogel L., and Marabelle A. Rationale for anti-OX40 cancer immunotherapy. [2016] Euro-pean Journal of Cancer (52) : 50-66.

8. Attarbaschi A., Carraro E., Abla O., Barzi-lai-Birenboim S., Bomken S., Brugieres L., Bu-banska E., Burkhardt B., Chiang A.K.S., Csoka M., Fedorova A., Jazbec J., Kabickova E., Krenova Z., Lazic J., Loeffen J., Mann G., Niggli F., Miakova N., Osumi T., Ronceray L., Uyttebroeck A., Williams D., Woessmann W., Wrobel G., Pillon M., European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL), and International Berlin-Frankfur t-Muns-ter (i-BFM) Study Group Non-Hodgkin lymphoma and pre-existing conditions: Spectrum, clinical cha-racteristics and outcome in 213 children and adoles-cents. [2016] Haematologica (101) 12 : 1581-1591.

9. Bachy E., Estell J.A., Van de Neste E., Bouabdal-lah R., Bargay J., Delmer A., Gelas-Dore B., Gomes da Silva M., Fitoussi O., Belada D., Maisonneuve H., Intragumtornchai T., Lamy T., Dartigues P., Francis Seymour J., and Salles G. Statin use is safe and does not impact prognosis in patient with de novo follicu-lar lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study. [2016] American Journal of Hematology (91) 4 : 410-415.

10. Baciarello G. and Sternberg C.N. Treatment of metastatic castration-resistant prostate cancer

(mCRPC) with enzalutamide. [2016] Critical Reviews in Oncology/Hematology (106) : 14-24. 11. Bakker M.F., Peeters P.H.M., Klaasen V.M., Bue-no-De-Mesquita H.B., Jansen E.H.J.M., Ros M.M., Travier N., Olsen A., Tjonneland A., Overvad K., Rinaldi S., Romieu I., Brennan P., Boutron-Ruault M.C., Perquier F., Cadeau C., Boeing H., Aleksan-drova K., Kaaks R., Kuhn T., Trichopoulou A., La-giou P., Trichopoulos D., Vineis P., Krogh V., Pani-co S., Masala G., Tumino R., Weiderpass E., Skeie G., Lund E., Quiros J.R., Ardanaz E., Navarro C., Amiano P., Sanchez M.J., Buckland G., Ericson U., Sonestedt E., Johansson M., Sund M., Travis R.C., Key T.J., Khaw K.T., Wareham N., Riboli E., and Van Gils C.H. Plasma carotenoids, Vitamin C, tocophe-rols, and retinol and the risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition cohort. [2016] American Journal of Clinical Nutrition (103) 2 : 454-464.

12. Baracco E.E., Pietrocola F., Buque A., Bloy N., Senovilla L., Zitvogel L., Vacchelli E., and Kroemer G. Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against car-cinogen-induced breast cancer. [2016] Oncoimmuno-logy (5) 6 : e1139275.

13. Bardo-Brouard P., Vieillard V., Shekarian T., Marabelle A., Astier A., and Paul M. Stability of ipi-limumab in its original vial after opening allows its use for at least 4 weeks and facilitates pooling of re-sidues. [2016] European Journal of Cancer (58) : 8-16.

14. Bazarbachi A., Labopin M., Kharfan-Dabaja M.A., Schwerdtfeger R., Volin L., Bourhis J.H., So-cie G., Daguindau E., Gedde-Dahl T., Rambaldi A., Karas M., Schlimok G., Blaise D., Chevallier P., Ma-lard F., Schmid C., Esteve J., Nagler A., and Mohty M. Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outco-me strongly correlates with disease status. [2016] Haematologica (101) 1 : E34-E37.

15. Benderra M.A., Aspeslagh S., Postel-Vinay S., Bigot L., de Baere T., Loriot Y., Lacroix L., Massard C., Vassal G., Andre F., and Soria J.C. Acquired EGFR mutation as the potential resistance driver to crizoti-nib in a MET-Mutated Tumor. [2016] Journal of Thora-cic Oncology (11) 2 : e21-e23.

16. Benhamou Y., Paintaud G., Azoulay E., Poullin P., Galicier L., Desvignes C., Baudel J.L., Peltier J., Mira J.P., Pene F., Presne C., Saheb S., Deligny C., Rousseau A., Feger F., Veyradier A., and Coppo P. Efficacy of a rituximab regimen based on B cell de-pletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter non-comparative study. [2016] American Journal of Hematology (91) 12 : 1246-1251.

17. Bentivegna E., Gouy S., Maulard A., Pautier P., Leary A., Colombo N., and Morice P. Fertility-spa-ring surgery in epithelial ovarian cancer: a syste-matic review of oncological issues. [2016] Annals of Oncology (27) 11 : 1994-2004.

18. Berchem G., Noman M.Z., Bosseler M., Paggetti J., Baconnais S., Le cam E., Nanbakhsh A., Mous-say E., Mami-Chouaib F., Janji B., and Chouaib S. Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-β and miR23a transfer. [2016] Oncoimmunology (5) 4 : e1062968.

19. Beroud C., Letovsky S.I., Braastad C.D., Capu-to S.M., Beaudoux O., Bignon Y.J., Bressac-de P.B., Bronner M., Buell C.M., Collod-Beroud G., Coulet F., Derive N., Divincenzo C., Elzinga C.D., Garrec

C., Houdayer C., Karbassi I., Lizard S., Love A., Muller D., Nagan N., Nery C.R., Rai G., Revillion F., Salgado D., Sevenet N., Sinilnikova O., Sobol H., Stoppa-Lyonnet D., Toulas C., Trautman E., Vaur D., Vilquin P., Weymouth K.S., Willis A., Eisenberg M., and Strom C.M. BRCA Share: A Collection of Clinical BRCA Gene Variants. [2016] Human Mutation (37) 12 : 1318-1328.

20. Besse B., Charrier M., Lapierre V., Dansin E., Lantz O., Planchard D., Le Chevalier T., Livartoski A., Barlesi F., Laplanche A., Ploix S., Vimond N., Pe-guillet I., Théry C., Lacroix L., Zoernig I., Dhodapkar K., Dhodapkar M., Viaud S., Soria J.C., Reiners K.S., Pogge von Strandmann E., Vély F., Rusakiewicz S., Eggermont A., Pitt J.M., Zitvogel L., and Chaput N. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NS-CLC. [2016] Oncoimmunology (5) 4 : e1071008.

21. Bibi S., Zhang Y., Hugonin C., Mangean M.D., He L., Wedeh G., Launay J.M., Van Rijn S., Wurdinger T., Louache F., and Arock M. A new humanized in vivo model of KIT D816V+ advanced systemic masto-cytosis monitored using a secreted luciferase. [2016] Oncotarget (7) 50 : 82985-83000

22. Billiet C., Peeters S., Decaluwe H., Vansteenkiste J., Dooms C., Deroose C.M., Hendrikx M., De Leyn P., Bulens P., Karim R., Le Pechoux C., Mebis J., and De Ruysscher D. Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection. [2016] Jour-nal of Thoracic Oncology (11) 11 : 1940-1953.

23. Billiet C., De Ruysscher D., Peeters S., Deca-luwe H., Vansteenkiste J., Dooms C., Deroose C.M., De Leyn P., Hendrikx M., Bulens P., Le Pechoux C., and Mebis J. Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III-N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications for Postoperative Radiothe-rapy Target Volumes. [2016] Journal of Thoracic Onco-logy (11) 9 : 1538-1549.

24. Blanchard P., Ribassin-Majed L., Lee A., and Pignon J.P. Comment on «Chemoradiotherapy re-gimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis», pu-blished in Eur J Cancer 51 (2015), 1570-1579. [2016] European Journal of Cancer (56) : 183-185.

25. Bolkestein M., de Blois E., Koelewijn S.J., Eg-germont A.M., Grosveld F., de Jong M., and Koning G.A. Investigation of Factors Determining the En-hanced Permeability and Retention Effect in Subcu-taneous Xenografts. [2016] Journal of Nuclear Medi-cine (57) 4 : 601-607.

26. Bonnefoi H., Grellety T., Tredan O., Saghatchian M., Dalenc F., Mailliez A., L’Haridon T., Cottu P., Aba-die-Lacourtoisie S., You B., Mousseau M., Dauba J., Del Piano F., Desmoulins I., Coussy F., Madranges N., Grenier J., Bidard F.C., Proudhon C., MacGrogan G., Orsini C., Pulido M., and Gonçalves A. A phase II trial of abiraterone acetate plus prednisone in pa-tients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). [2016] Annals of Oncology (27) 5 : 812-818 .

27. Bonnet F., Affret A., Boutron-Ruault M.C., Balkau B., Clavel-Chapelon F., and Fagherazzi G. Response to Comment on Bonnet et al. Association Between Handedness and Type 2 Diabetes: The E3N Study. Diabetes Care 2015;38:e199. [2016] Diabetes Care (39) 3 : e47.

28. Bouchahda M., Boige V., Smith D., Karaboue A., Ducreux M., Hebbar M., Lepere C., Focan C., Guim-baud R., Innominato P., Awad S., Carvalho C., Tu-

Publications internationales Gustave Roussy 2016

AVEC IMPACT FACTOR SUPÉRIEUR ENTRE 5 ET 10 (IF 2015)HORS MEETING/POSTER ABSTRACTS, CONFERENCE DOCUMENTS ET ERRATUM

molo S., Truant S., de Baere T., Castaing D., Rougier P., Morere J.F., Taieb J., Adam R., and Levi F. Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infu-sion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. [2016] European Journal of Cancer (68) : 163-172.

29. Bouchet S., Poulette S., Titier K., Moore N., Lassalle R., Abouelfath A., Italiano A., Chevreau C., Bompas E., Collard O., Duffaud F., Rios M., Cupissol D., Adenis A., Ray-Coquard I., Bouché O., Le Cesne A., Bui B., Blay J.Y., and Molimard M. Relationship between imatinib trough concentration and outco-mes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting. [2016] Euro-pean Journal of Cancer (57) : 31-38.

30. Bourseguin J., Bonet C., Renaud E., Pandiani C., Boncompagni M., Giuliano S., Pawlikowska P., Karmous-Benailly H., Ballotti R., Rosselli F., and Bertolotto C. FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cells. [2016] Scientific Re-ports (6) : 36539.

31. Boussemart L., Girault I., Malka-Mahieu H., Mateus C., Routier E., Rubington M., Kamsu-Kom N., Thomas M., Tomasic G., Agoussi S., Breckler M., Laporte M., Lacroix L., Eggermont A.M., Cavalcanti A., Grange F., Adam J., Vagner S., and Robert C. Se-condary tumors arising in patients undergoing BRAF inhibitor therapy exhibit increased BRAF-CRAF hete-rodimerization. [2016] Cancer Research (76) 6 : 1476-1484.

32. Boutet M., Gauthier L., Leclerc M., Gros G., De Montpreville V., Theret N., Donnadieu E., and Ma-mi-Chouaib F. TGFbeta signaling intersects with CD103 integrin signaling to promote T-Lymphocyte accumulation and antitumor activity in the lung tu-mor microenvironment. [2016] Cancer Research (76) 7 : 1757-1769.

33. Bressac-de Paillerets B., Vabres P., and Tho-mas L. Genetic Testing for Melanoma-Where Are We With Moderate-Penetrance Genes? [2016] JAMA Der-matology (152) 4 : 375-376.

34. Bridgewater J., Lopes A., Wasan H., Malka D., Jensen L., Okusaka T., Knox J., Wagner D., Cunnin-gham D., Shannon J., Goldstein D., Moehler M., Be-kaii-Saab T., McNamara M., and Valle J. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. [2016] Annals of Onco-logy (27) 1 : 134-140.

35. Broutin S., Stewart A., Thavasu P., Paci A., Bi-dart J.M., and Banerji U. Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer. [2016] British Journal of Cancer (115) 5 : 549-552.

36. Brunet L.R., Hagemann T., Andrew G., Mudan S., and Marabelle A. Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer? [2016] Oncoimmu-nology (5) 4 : e1112942.

37. Buque A., Bloy N., Aranda F., Cremer I., Eg-germont A., Fridman W.H., Fucikova J., Galon J., Spisek R., Tartour E., Zitvogel L., Kroemer G., and Galluzzi L. Trial Watch - Small molecules targe-ting the immunological tumor microenvironment for cancer therapy. [2016] Oncoimmunology (5) 6 : e1149674.

38. Burdett S., Rydzewska L., Tierney J., Fisher D., Parmar M.K.B., Arriagada R., Pignon J.P., Le Pechoux C., Brichet A.H., Lafitte J.J., Girling D.J., Parmar M.K.B., Rydzewska L.H.M., Stephens R.J., Stewart L.A., Tierney J.F., Dautzenberg B., Debe-vec M., Kovac V., Gregor A., Park J.H., Piantadosi S., Pignon J.P., Rocmans P., Souhami R., Torri V., Van Houtte P., Trodella L., and Wang M. Postoperative radiotherapy for non-small cell lung cancer. [2016] Cochrane Database of Systematic Reviews (2016) 10 : CD002142.

39. Buyse M., Hurvitz S.A., Andre F., Jiang Z., Burris H.A., Toi M., Eiermann W., Lindsay M.A., and Sla-mon D. Statistical controversies in clinical research: Statistical significance-too much of a good thing. [2016] Annals of Oncology (27) 5 : 760-762. 40. Cabarrou B., Boher J.M., Bogart E., Tresch-Bruneel E., Penel N., Ravaud A., Escudier B., Mahier Ait-Oukhatar C., Delord J.P., Roche H., and Filleron T. How to report toxicity associated with targeted the-rapies? [2016] Annals of Oncology (27) 8 : 1633-1638.

41. Cadeau C., Fournier A., Mesrine S., Clavel-Cha-pelon F., Fagherazzi G., and Boutron-Ruault M.C. Postmenopausal breast cancer risk and interactions between body mass index, menopausal hormone therapy use, and vitamin D supplementation: Evi-dence from the E3N cohort. [2016] International Jour-nal of Cancer (139) 10 : 2193-2200.

42. Cadeau C., Fournier A., Mesrine S., Clavel-Cha-pelon F., Fagherazzi G., and Boutron-Ruault M.C. Vitamin C supplement intake and postmenopausal breast cancer risk: interaction with dietary vitamin C. [2016] American Journal of Clinical Nutrition (104) 1 : 228-234.

43. Calvet C.Y. and Mir L.M. The promising alliance of anti-cancer electrochemotherapy with immuno-therapy. [2016] Cancer and Metastasis Reviews (35) 2 : 165-177.

44. Calvo E., Schmidinger M., Heng D.Y., Grunwald V., and Escudier B. Improvement in survival end points of patients with metastatic renal cell carcino-ma through sequential targeted therapy. [2016] Can-cer Treatment Reviews (50) : 109-117. 45. Cammas A., Lacroix-Triki M., Pierredon S., Le Bras M., Iacovoni J.S., Teulade-Fichou M.P., Favre G., Roche H., Filleron T., Millevoi S., and Vagner S. hnRNP A1-mediated translational regulation of the G quadruplex-containing RON receptor tyrosine kinase mRNA linked to tumor progression. [29-3-2016] On-cotarget (7) 13 : 16793-16805.

46. Campbell J., Ryan C.J., Brough R., Bajrami I., Pemberton H.N., Chong I.Y., Costa-Cabral S., Frankum J., Gulati A., Holme H., Miller R., Postel-Vi-nay S., Rafiq R., Wei W., Williamson C.T., Quigley D.A., Tym J., Al-Lazikani B., Fenton T., Natrajan R., Strauss S.J., Ashworth A., and Lord C.J. Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. [2016] Cell Reports (14) 10 : 2490-2501.

47. Carceller F., Bautista F.J., Jimenez I., Hla-dun-Alvaro R., Giraud C., Bergamaschi L., Dan-dapani M., Aerts I., Doz F., Frappaz D., Casanova M., Morland B., Hargrave D.R., Marshall L.V., Vassal G., Pearson A.D., Geoerger B., and Moreno L. Prognos-tic factors of overall survival in children and adoles-cents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study. [2016] European Journal of Cancer (67) : 130-140.

48. Castanon E. Anti-PD1 induced pneumonitis: cap-turing the hidden enemy. [2016] Clinical Cancer Re-search (22) 24 : 5956-5958.

49. Castro-Smirnov F.A., Pietrement O., Aranda P., Bertrand J.R., Ayache J., Le cam E., Ruiz-Hitzky E., and Lopez B.S. Physical interactions between DNA and sepiolite nanofibers, and potential application for DNA transfer into mammalian cells. [2016] Scientific Reports (6) : 36341.

50. Castro-Vega L.J., Kiando S.R., Burnichon N., Buffet A., Amar L., Simian C., Berdelou A., Galan P., Schlumberger M., Bouatia-Naji N., Favier J., Bres-sac-de P.B., and Gimenez-Roqueplo A.P. The MITF, p.E318K variant as a risk factor for pheochromocy-toma and paraganglioma. [2016] Journal of Clinical Endocrinology & Metabolism (101) 12 : 4764-4768. 51. Chabanon R.M., Pedrero M., Lefebvre C., Ma-rabelle A., Soria J.C., and Postel-Vinay S. Mutatio-nal Landscape and Sensitivity to Immune Checkpoint Blockers. [2016] Clinical Cancer Research (22) 17 : 4309-4321.

52. Champiat S., Lambotte O., Barreau E., Belkhir R., Berdelou A., Carbonnel F., Cauquil C., Chanson P., Collins M., Durrbach A., Ederhy S., Feuillet S., François H., Lazarovici J., Le Pavec J., De Martin E., Mateus C., Michot J.M., Samuel D., Soria J.C., Robert C., Eggermont A., and Marabelle A. Mana-gement of immune checkpoint blockade dysimmune toxicities: A collaborative position paper. [2016] An-nals of Oncology (27) 4 : 559-574.

53. Chargari C., Magne N., Guy J.B., Rancoule C., Levy A., Goodman K.A., and Deutsch E. Optimize and refine therapeutic index in radiation therapy: Overview of a century. [2016] Cancer Treatment Re-views (45) : 58-67.

54. Chargari C., Goodman K.A., Diallo I., Guy J.B., Rancoule C., Cosset J.M., Deutsch E., and Magne N. Risk of second cancers in the era of modern radia-tion therapy: does the risk/benefit analysis overcome theoretical models? [2016] Cancer and Metastasis Re-views (35) 2 : 277-288. 55. Charles C., Bungener C., Razavi D., Mateus C., Routier E., Lanoy E., Verschoore M., Robert C., and Dauchy S. Impact of dermatologic adverse events in-duced by targeted therapies on quality of life. [2016] Critical Reviews in Oncology/Hematology (101) : 158-168.

56. Cheminant M., Derrieux C., Touzart A., Schmit S., Grenier A., Trinquand A., Delfau-Larue M.H., Lhermitte L., Thieblemont C., Ribrag V., Cheze S., Sanhes L., Jardin F., Lefrère F., Delarue R., Hos-ter E., Dreyling M., Asnafi V., Hermine O., and Ma-cintyre E. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: An EU-MCL and LYSA study. [2016] Haematologica (101) 3 : 336-345.

57. Chi K.N., Kheoh T., Ryan C.J., Molina A., Bellmu-nt J., Vogelzang N.J., Rathkopf D.E., Fizazi K., Kan-toff P.W., Li J., Azad A.A., Eigl B.J., Heng D.Y.C., Jo-shua A.M., De Bono J.S., and Scher H.I. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate can-cer treated with abiraterone acetate after docetaxel. [2016] Annals of Oncology (27) 3 : 454-460. 58. Chicard M., Boyault S., Colmet D.L., Richer W., Gentien D., Pierron G., Lapouble E., Bellini A., Cle-ment N., Iacono I., Brejon S., Carrere M., Reyes C., Hocking T., Bernard V., Peuchmaur M., Corradini N., Faure-Conter C., Coze C., Plantaz D., Defa-chelles A.S., Thebaud E., Gambart M., Millot F., Val-teau-Couanet D., Michon J., Puisieux A., Delattre O., Combaret V., and Schleiermacher G. Genomic copy number profiling using circulating free tumor DNA highlights heterogeneity in neuroblastoma. [2016] Clinical Cancer Research (22) 22 : 5564-5573.

59. Chomel J.C., Bonnet M.L., Sorel N., Sloma I., Bennaceur-Griscelli A., Rea D., Legros L., Mar-faing-Koka A., Bourhis J.H., Ame S., Guerci-Bresler A., Rousselot P., and Turhan A.G. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine ki-nase inhibitors and the impact of therapy disconti-nuation. [2016] Oncotarget (7) 23 : 35293-35301.

60. Choueiri T.K., Fishman M.N., Escudier B., Mc-Dermott D.F., Drake C.G., Kluger H., Stadler W.M., Perez-Gracia J.L., McNeel D.G., Curti B., Harrison M.R., Plimack E.R., Appleman L., Fong L., Albiges L., Cohen L., Young T.C., Chasalow S.D., Ross-MacDo-nald P., Srivastava S., Jure-Kunkel M., Kurland J.F., Simon J.S., and Sznol M. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. [2016] Clinical Cancer Research (22) 22 : 5461-5471.

61. Chousterman B.G., Boissonnas A., Poupel L., de Chanville C.B., Adam J., Tabibzadeh N., Licata F., Lukaszewicz A.C., Lombes A., Deterre P., Payen D., and Combadiere C. Ly6C(high) Monocytes Pro-tect against Kidney Damage during Sepsis via a CX3CR1-Dependent Adhesion Mechanism. [2016] Journal of the American Society of Nephrology (27) 3 : 792-803.

62. Coiffier B., Thieblemont C., de Guibert S., Du-puis J., Ribrag V., Bouabdallah R., Morschhauser F., Navarro R., Le Gouill S., Haioun C., Houot R., Casasnovas O., Holte H., Lamy T., Broussais F., Pay-rard S., Hatteville L., and Tilly H. A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. [2016] Bri-tish Journal of Haematology (173) 5 : 722-730.

63. Colombo N., Creutzberg C., Amant F., Bosse T., González-Martón A., Ledermann J., Marth C., Nout R., Querleu D., Mirza M.R., Sessa C., Abal M., Altun-dag O., Amant F., Banerjee S., Bosse T., Casado A., De Agustín L.C., Cibula D., Colombo N., Creutzberg C., Del Campo J.-M., Emons G., Goffin F., González-Martín A., Greggi S., Haie-Meder C., Katsaros D., Kesic V., Kurzeder C., Lax S., Lécuru F., Leder-mann J., Levy T., Lorusso D., Mäenpää J., Marth C., Matias-Guiu X., Morice P., Nijman H.W., Nout R., Powell M., Querleu D., Mirza M.R., Reed N., Rodo-lakis A., Salvesen H., Sehouli J., Sessa C., Taylor A., Westermann A., and Zeimet A.G. ESMO-ESGO-ES-TRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. [2016] Annals of Oncology (27) 1 : 16-41.

64. Commo F., Guinney J., Ferté C., Bot B., Lefebvre C., Soria J.C., and André F. RCGH: A comprehensive array-based genomic profile platform for precision medicine. [2016] Bioinformatics (32) 9 : 1402-1404.

65. Communal L., Vilasco M., Hugon-Rodin J., Cour-tin A., Mourra N., Lahlou N., Le Guillou M., Perrault de Jotemps M., Chauvet M.P., Chaouat M., Pujol P., Feunteun J., Delaloge S., Forgez P., and Gompel A. Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations. [2016] Oncotarget (7) 29 : 45317-45330.

66. Congras A., Barasc H., Canale-Tabet K., Plis-son-Petit F., Delcros C., Feraud O., Oudrhiri N., Hadadi E., Griscelli F., Bennaceur-Griscelli A., Turhan A., Afanassieff M., Ferchaud S., Pinton A., Yerle-Bouissou M., and Acloque H. Non integrative strategy decreases chromosome instability and im-proves endogenous pluripotency genes reactivation in porcine induced pluripotent-like stem cells. [2016] Scientific Reports (6) : 27059.

67. Conroy T., Bachet J.B., Ayav A., Huguet F., Lambert A., Caramella C., Maréchal R., Van Laethem J.L., and Ducreux M. Current standards and new innovative approaches for treatment of pancreatic cancer. [2016] European Journal of Can-cer (57) : 10-22.

68. Cox D.G., Curtit E., Romieu G., Fumoleau P., Rios M., Bonnefoi H., Bachelot T., Soulie P., Jouannaud C., Bourgeois H., Petit T., Tennevet I., Assouline D., Mathieu M.C., Jacquin J.P., Lavau-Denes S., Darut-Jouve A., Ferrero J.M., Tarpin C., Levy C., Delecroix V., Trillet-Lenoir V., Cojocarasu O., Meu-nier J., Pierga J.Y., Faure-Mercier C., Blanche H., Sahbatou M., Boland A., Bacq D., Besse C., Deleuze J.F., Pauporte I., Thomas G., and Pivot X. GWAS in the SIGNAL/PHARE clinical cohort restricts the as-sociation between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer pa-tients. [2016] Oncotarget (7) 47 : 77358-77364.

69. Craddock C., Labopin M., Robin M., Finke J., Chevallier P., Yakoub-Agha I., Bourhis J.H., Senge-lov H., Blaise D., Luft T., Hallek M., Kroger N., Na-gler A., and Mohty M. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. [2016] Haematologica (101) 7 : 879-883.

70. Dartois L., Fagherazzi G., Baglietto L., Bou-tron-Ruault M.C., Delaloge S., Mesrine S., and Clavel-Chapelon F. Proportion of premenopausal and postmenopausal breast cancers attributable to known risk factors: Estimates from the E3N-EPIC cohort. [2016] International Journal of Cancer (138) 10 : 2415-2427.

71. Das A.M., Koljenovic S., Oude Ophuis C.M.C., Van Der Klok T., Galjart B., Nigg A.L., Van Cappellen W.A., Noordhoek Hegt V., Dinjens W.N.M., Atmodi-medjo P.N., Vermeulen C.E., Verhoef C., Eggermont A.M.M., and Ten Hagen T.L.M. Association of TIMP3 expression with vessel density, macrophage infiltra-tion and prognosis in human malignant melanoma. [2016] European Journal of Cancer (53) : 135-143.

72. Das A.M., Pescatori M., Vermeulen C.E., Rens J.A.P., Seynhaeve A.L.B., Koning G.A., Eggermont A.M.M., and Ten Hagen T.L.M. Melanomas prevent endothelial cell death under restrictive culture condi-tions by signaling through AKT and p38 MAPK/ ERK-1/2 cascades. [2016] Oncoimmunology (5) 10 : e1219826.

73. Das A.M., Bolkestein M., Van Der Klok T., Oude Ophuis C.M., Vermeulen C.E., Rens J.A., Dinjens W.N., Atmodimedjo P.N., Verhoef C., Koljenovic S., Smits R., ten Hagen T.L., and Eggermont A.M. Tis-sue inhibitor of metalloproteinase-3 (TIMP3) expres-sion decreases during melanoma progression and inhibits melanoma cell migration. [2016] European Journal of Cancer (66) : 34-46.

74. de Charette M., Marabelle A., and Houot R. Tur-ning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy? [2016] European Journal of Cancer (68) : 134-147. 75. de Menorval M.A., Andre F.M., Silve A., Dalmay C., Francais O., Le Pioufle B., and Mir L.M. Electric pulses: a flexible tool to manipulate cytosolic calcium concentrations and generate spontaneous-like cal-cium oscillations in mesenchymal stem cells. [2016] Scientific Reports (6) : 32331. 76. De Ruysscher D., Lueza B., Le Pechoux C., John-son D.H., O’Brien M., Murray N., Spiro S., Wang X., Takada M., Lebeau B., Blackstock W., Skarlos D., Baas P., Choy H., Price A., Seymour L., Arriagada R., and Pignon J.P. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: use-fulness of the individual patient data meta-analysis. [2016] Annals of Oncology (27) 10 : 1818-1828.

77. De Santis M., Wiechno P.J., Bellmunt J., Lucas C., Su W.C., Albiges L., Lin C.C., Senkus-Konefka E., Flechon A., Mourey L., Necchi A., Loidl W.C., Retz M.M., Vaissière N., and Culine S. Vinflunine-gem-citabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with ad-vanced urothelial carcinoma: Results of an inter-national randomized phase II trial (JASINT1). [2016] Annals of Oncology (27) 3 : 449-454 .

78. De Velasco G., Krajewski K.M., Albiges L., Awad M.M., Bellmunt J., Hodi F.S., and Choueiri T.K. Ra-diologic heterogeneity in responses to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma. [2016] Cancer Immunology Research (4) 1 : 12-17.

79. Debets R., Donnadieu E., Chouaib S., and Cou-kos G. TCR-engineered T cells to treat tumors: Seeing but not touching? [2016] Seminars in Immuno-logy (28) 1 : 10-21.

80. Delaloge S., Perol D., Courtinard C., Brain E., Asselain B., Bachelot T., Debled M., Dieras V., Cam-pone M., Levy C., Jacot W., Lorgis V., Veyret C., Da-lenc F., Ferrero J.M., Uwer L., Kerbrat P., Goncal-ves A., Mouret-Reynier M.A., Petit T., Jouannaud C., Vanlemmens L., Chenuc G., Guesmia T., Robain M., and Cailliot C. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. [2016] Annals of Oncology (27) 9 : 1725-1732.

81. Delaloge S., Bonastre J., Borget I., Garbay J.R., Fontenay R., Boinon D., Saghatchian M., Mathieu M.C., Mazouni C., Rivera S., Uzan C., Andre F., Dro-main C., Boyer B., Pistilli B., Azoulay S., Rimareix F., Bayou E.H., Sarfati B., Caron H., Ghouadni A., Leymarie N., Canale S., Mons M., Arfi-Rouche J., Arnedos M., Suciu V., Vielh P., and Balleyguier C. The challenge of rapid diagnosis in oncology: Dia-gnostic accuracy and cost analysis of a large-scale one-stop breast clinic. [2016] European Journal of Cancer (66) : 131-137.

82. Deplanque G., Gervais R., Vergnenegre A., Fal-chero L., Souquet P.J., Chavaillon J.M., Taviot B., Fraboulet G., Saal H., Robert C., and Chosidow O. Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A rando-mized, open-label trial. [2016] Journal of the American Academy of Dermatology (74) 6 : 1077-1085.

83. Dercle L., Deandreis D., Terroir M., Leboulleux S., Lumbroso J., and Schlumberger M. Evaluation of 124I PET/CT and 124I PET/MRI in the management of patients with differentiated thyroid cancer. [2016] European Journal of Nuclear Medicine and Molecular Imaging (43) 6 : 1006-1010.

84. Dercle L., Ammari S., Champiat S., Massard C., Ferte C., Taihi L., Seban R.D., Aspeslagh S., Mahjoubi L., Kamsu-Kom N., Robert C., Marabelle A., Schlumberger M., Soria J.C., and Postel-Vinay S. Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy. [2016] European Journal of Cancer (65) : 33-42.

85. Destouches D., Sader M., Terry S., Marchand C., Maille P., Soyeux P., Carpentier G., Semprez F., Ceraline J., Allory Y., Courty J., de la Taille A., and Vacherot F. Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein anta-gonist N6L in prostate cancer. [2016] Oncotarget (7) 43 : 69397-69411.

86. Deutsch E., Haie-Meder C., Bayar M.A., Mondini M., Laporte M., Mazeron R., Adam J., Varga A., Vas-sal G., Magné N., Chargari C., Lanoy E., Pautier P., Levy A., and Soria J.C. Phase I trial evaluating the antiviral agent Cidofovir in combination with chemo-radiation in cervical cancer patients. [2016] Oncotar-get (7) 18 : 25549-25557.

87. Dewi N.U., Boshuizen H.C., Johansson M., Vi-neis P., Kampman E., Steffen A., Tjonneland A., Halkjaer J., Overvad K., Severi G., Fagherazzi G., Boutron-Ruault M.C., Kaaks R., Li K., Boeing H., Trichopoulou A., Bamia C., Klinaki E., Tumino R., Palli D., Mattiello A., Tagliabue G., Peeters P.H., Vermeulen R., Weiderpass E., Gram I.T., Huerta J.M., Agudo A., Sanchez M.J., Ardanaz E., Dorron-soro M., Quiros J.R., Sonestedt E., Johansson M., Grankvist K., Key T., Khaw K.T., Wareham N., Cross A.J., Norat T., Riboli E., Fanidi A., Muller D., and Bueno-De-Mesquita H.B. Anthropometry and the risk of lung cancer in EPIC. [2016] American Journal of Epidemiology (184) 2 : 129-139. 88. Dhermain F. and Deutsch E. Stereotactic radia-tion and checkpoint inhibitors in melanoma patients with BM: A question of drug, timing or both? [2016] Annals of Oncology (27) 3 : 371-372. 89. Djeghloul D., Kuranda K., Kuzniak I., Barbieri D., Naguibneva I., Choisy C., Bories J.C., Dosquet C., Pla M., Vanneaux V., Socie G., Porteu F., Garrick D., and Goodhardt M. Age-Associated Decrease of the Histone Methyltransferase SUV39H1 in HSC Per-turbs Heterochromatin and B Lymphoid Differentia-tion. [2016] Stem Cell Reports (6) 6 : 970-984. 90. Dmitriev P., Bou S.Y., Dib C., Ansseau E., Barat A., Hamade A., Dessen P., Robert T., Lazar V., Louzada R.A., Dupuy C., Zakharova V., Carnac G., Lipinski M., and Vassetzky Y.S. DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients. [2016] Free Radical Biology and Medicine (99) : 244-258.

91. Dmitriev P., Kiseleva E., Kharchenko O., Ivash-kin E., Pichugin A., Dessen P., Robert T., Coppee F., Belayew A., Carnac G., Laoudj-Chenivesse D., Lipinski M., Vasiliev A., and Vassetzky Y.S. Dux4 controls migration of mesenchymal stem cells through the Cxcr4-Sdf1 axis. [2016] Oncotarget (7) 40 : 65090-65108.

92. Ducreux M. and Pignon J.P. Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block? [2016] European Journal of Cancer (69) : 178-179.

93. Dugue P.A., Brinkman M.T., Milne R.L., Wong E.M., FitzGerald L.M., Bassett J.K., Joo J.E., Jung C.H., Makalic E., Schmidt D.F., Park D.J., Chung J., Ta A.D., Bolton D.M., Lonie A., Longano A., Hopper J.L., Severi G., Saffery R., English D.R., Southey M.C., and Giles G.G. Genome-wide measures of DNA methylation in peripheral blood and the risk of urothelial cell carcinoma: a prospective nested case-control study. [2016] British Journal of Cancer (115) 6 : 664-673.

94. Dulphy N., Chretien A.S., Khaznadar Z., Fauriat C., Nanbakhsh A., Caignard A., Chouaib S., Olive D., and Toubert A. Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells. [2016] Frontiers in Immunology (7) : 94.

95. Dumas A., Berger C., Auquier P., Michel G., Fresneau B., Sétcheou Allodji R., Haddy N., Rubino C., Vassal G., Valteau-Couanet D., Thouvenin-Dou-let S., Casagranda L., Pacquement H., El-Fayech C., Oberlin O., Guibout C., and De Vathaire F. Educatio-nal and occupational outcomes of childhood cancer survivors 30 years after diagnosis: A French cohort study. [2016] British Journal of Cancer (114) 9 : 1060-1068.

96. Duvallet E., Boulpicante M., Yamazaki T., Daskalogianni C., Prado Martins R., Baconnais S., Manoury B., Fahraeus R., and Apcher S. Exo-some-driven transfer of tumor-associated Pioneer Translation Products (TA-PTPs) for the MHC class I cross-presentation pathway. [2016] Oncoimmunology (5) 9 : e1198865.

97. Eggermont A.M. Adjuvant ipilimumab in stage III melanoma: New landscape, new questions. [2016] European Journal of Cancer (69) : 39-42.

98. Eggermont A.M.M., Suciu S., Rutkowski P., Kruit W.H., Punt C.J., Dummer R., Salès F., Keil-holz U., De Schaetzen G., and Testori A. Long term follow up of the EORTC 18952 trial of adjuvant the-rapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interfe-ron-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. [2016] European Journal of Cancer (55) : 111-121.

99. Emaus M.J., Peeters P.H., Bakker M.F., Over-vad K., Tjonneland A., Olsen A., Romieu I., Ferrari P., Dossus L., Boutron-Ruault M.C., Baglietto L., Fortner R.T., Kaaks R., Boeing H., Trichopoulou A., Lagiou P., Trichopoulos D., Masala G., Pala V., Pa-nico S., Tumino R., Polidoro S., Skeie G., Lund E., Weiderpass E., Ramon Quiros J., Travier N., San-chez M.J., Chirlaque M.D., Ardanaz E., Dorronsoro M., Winkvist A., Wennberg M., Bueno-de-Mesquita H., Khaw K.T., Travis R.C., Key T.J., Aune D., Gunter M., Riboli E., and van Gils C.H. Vegetable and fruit consumption and the risk of hormone receptor-de-fined breast cancer in the EPIC cohort. [2016] Ameri-can Journal of Clinical Nutrition (103) 1 : 168-177.

100. Engert A., Balduini C., Brand A., Coiffier B., Cordonnier C., Dohner H., De Wit T.D., Eichinger S., Fibbe W., Green T., De Haas F., Iolascon A., Jaffredo T., Rodeghiero F., Sall Es G., Schuringa J.J., Andre M., Andre-Schmutz I., Bacigalupo A., Bochud P.Y., Den Boer M., Bonini C., Camaschella C., Cant A., Cappellini M.D., Cazzola M., Celso C.L., Dimopou-los M., Douay L., Dzierzak E., Einsele H., Ferreri A., De Franceschi L., Gaulard P., Gottgens B., Greina-cher A., Gresele P., Gribben J., De Haan G., Hansen J.B., Hochhaus A., Kadir R., Kaveri S., Kouskoff V., Kuhne T., Kyrle P., Ljungman P., Maschmeyer G., Mendez-Ferrer S., Milsom M., Mummery C., Ossenkoppele G., Pecci A., Peyvandi F., Philipsen S., Reitsma P., Ribera J.M., Risitano A., Rivella S., Ruf W., Schroeder T., Scully M., Socie G., Staal F., Stanworth S., Stauder R., Stilgenbauer S., Tama-ry H., Theilgaard-Monch K., Thein S.L., Tilly H., Trneny M., Vainchenker W., Vannucchi A.M., Viscoli C., Vrielink H., Zaaijer H., Zanella A., Zolla L., Zwa-ginga J.J., Martinez P.A., Van Den Akker E., Allard S., Anagnou N., Andolfo I., Andrau J.C., Angelucci E., Anstee D., Aurer I., Avet-Loiseau H., Aydinok Y., Bakchoul T., Balduini A., Barcellini W., Baruch D., Baruchel A., Bayry J., Bento C., Van Den Berg A., Bernardi R., Bianchi P., Bigas A., Biondi A., Bo-

honek M., Bonnet D., Borchmann P., Borregaard N., Broekkan S., Van Den Brink M., Brodin E., Bullinger L., Buske C., Butzeck B., Cammenga J., Campo E., Carbone A., Cervantes F., Cesaro S., Charbord P., Claas F., Cohen H., Conard J., Coppo P., Vives Cor-ron J.L., Da Costa L., Davi F., Delwel R., Dianzani I., Domanovic D., Donnelly P., Drnovsek T.D., Drey-ling M., Du M.Q., Dufour C., Durand C., Efremov D., Eleftheriou A., Elion J., Emonts M., Engelhardt M., Ezine S., Falkenburg F., Favier R., Federico M., Fe-naux P., Fitzgibbon J., Flygare J., Foa R., Forrester L., Galacteros F., Garagiola I., Gardiner C., Garraud O., Van Geet C., Geiger H., Geissler J., Germing U., Ghevaert C., Girelli D., Godeau B., Gokbuget N., Goldschmidt H., Goodeve A., Graf T., Graziadei G., Griesshammer M., Gruel Y., Guilhot F., Von Gunten S., Gyssens I., Halter J., Harrison C., Harteveld C., Hellstrom-Lindberg E., Hermine O., Higgs D., Hillmen P., Hirsch H., Hoskin P., Huls G., Inati A., Johnson P., Kattamis A., Kiefel V., Kleanthous M., Klump H., Krause D., Hovinga J.K., Lacaud G., La-croix-Desmazes S., Landman-Parker J., Legouill S., Lenz G., Von Lilienfeld-Toal M., Von Lindern M., Lopez-Guillermo A., Lopriore E., Lozano M., Macintyre E., Makris M., Mannhalter C., Martens J., Mathas S., Matzdorff A., Medvinsky A., Me-nendez P., Migliaccio A.R., Miharada K., Mikulska M., Minard V., Montalban C., De Montalembert M., Montserrat E., Morange P.E., Mountford J., Muc-kenthaler M., Muller-Tidow C., Mumford A., Nadel B., Navarro J.T., El Nemer W., Noizat-Pirenne F., O’Mahony B., Oldenburg J., Olsson M., Oostendorp R., Palumbo A., Passamonti F., Patient R., De La-tour R.P., Pflumio F., Pierelli L., Piga A., Pollard D., Raaijmakers M., Radford J., Rambach R., Koneti Rao A., Raslova H., Rebulla P., Rees D., Ribrag V., Rijneveld A., Rinalducci S., Robak T., Roberts I., Rodrigues C., Rosendaal F., Rosenwald A., Rule S., Russo R., Saglio G., Sanchez M., Scharf R.E., and Schlenke P. The european hematology associa-tion roadmap for european hematology research: A consensus document. [2016] Haematologica (101) 2 : 115-208.

101. Escande A., Haie-Meder C., Maroun P., Gouy S., Mazeron R., Leroy T., Bentivegna E., Morice P., Deutsch E., and Chargari C. Neutrophilia in local-ly advanced cervical cancer: A novel biomarker for image-guided adaptive brachytherapy? [2016] Onco-target (7) 46 : 74886-74894.

102. Escudier B., Molinie V., Bracarda S., Maroto P., Szczylik C., Nathan P., Negrier S., Weiss C., Porta C., Grunwald V., and Albiges L. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAP-TOR final analysis. [2016] European Journal of Cancer (69) : 226-235.

103. Escudier B., Porta C., Schmidinger M., Rioux-Leclercq N., Bex A., Khoo V., Gruenvald V., and Horwich A. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and fol-low-up. [2016] Annals of Oncology (27) suppl 5 : v58-v68.

104. Facchinetti F., Loriot Y., Cassin-Kuo M.S., Mahjoubi L., Lacroix L., Planchard D., Besse B., Auger N., Farace F., Remon J., Scoazec J.Y., Andre F., Soria J.C., and Friboulet L. Crizotinib-resistant ROS1 mutations reveal a predictive kinase inhibitor sensitivity model for. [2016] Clinical Cancer Research (22) 24 : 5983-5991.

105. Facchinetti F., Marabelle A., Rossi G., Soria J.C., Besse B., and Tiseo M. Moving immune check-point blockade in thoracic tumors beyond non-small cell lung cancer. [2016] Journal of Thoracic Oncology (11) 11 : 1819-1836.

106. Fanidi A., Muller D.C., Midttun O., Ueland P.M., Vollset S.E., Relton C., Vineis P., Weiderpass E., Skeie G., Brustad M., Palli D., Tumino R., Grioni S., Sacerdote C., Bueno-De-Mesquita H.B., Peeters P.H., Boutron-Ruault M.C., Kvaskoff M., Cadeau C., Huerta J.M., Sanchez M.J., Agudo A., Lasheras C., Quiros J.R., Chamosa S., Riboli E., Travis R.C., Ward H., Murphy N., Khaw K.T., Trichopoulou A., Lagiou P., Papatesta E.M., Boeing H., Kuehn T., Ka-tzke V., Steffen A., Johansson A., Brennan P., and Johansson M. Circulating vitamin D in relation to

cancer incidence and survival of the head and neck and oesophagus in the EPIC cohort. [2016] Scientific Reports (6) : 36017.

107. Fehringer G., Kraft P., Pharoah P.D., Eeles R.A., Chatterjee N., Schumacher F.R., Schildkraut J.M., Lindstrom S., Brennan P., Bickeboller H., Houlston R.S., Landi M.T., Caporaso N., Risch A., Amin Al O.A., Berndt S.I., Giovannucci E.L., Gron-berg H., Kote-Jarai Z., Ma J., Muir K., Stampfer M.J., Stevens V.L., Wiklund F., Willett W.C., Goode E.L., Permuth J.B., Risch H.A., Reid B.M., Bezieau S., Brenner H., Chan A.T., Chang-Claude J., Hudson T.J., Kocarnik J.K., Newcomb P.A., Schoen R.E., Slattery M.L., White E., Adank M.A., Ahsan H., Ait-tomaki K., Baglietto L., Blomquist C., Canzian F., Czene K., Dos-Santos-Silva I., Eliassen A.H., Figue-roa J.D., Flesch-Janys D., Fletcher O., Garcia-Clo-sas M., Gaudet M.M., Johnson N., Hall P., Hazra A., Hein R., Hofman A., Hopper J.L., Irwanto A., Jo-hansson M., Kaaks R., Kibriya M.G., Lichtner P., Liu J., Lund E., Makalic E., Meindl A., Muller-Myhsok B., Muranen T.A., Nevanlinna H., Peeters P.H., Peto J., Prentice R.L., Rahman N., Sanchez M.J., Sch-midt D.F., Schmutzler R.K., Southey M.C., Tamimi R., Travis R.C., Turnbull C., Uitterlinden A.G., Wang Z., Whittemore A.S., Yang X.R., Zheng W., Buchanan D.D., Casey G., Conti D.V., Edlund C.K., Gallinger S., Haile R.W., Jenkins M., Le M.L., Li L., Lindor N.M., Schmit S.L., Thibodeau S.N., Woods M.O., Rafnar T., Gudmundsson J., Stacey S.N., Stefansson K., Sulem P., Chen Y.A., Tyrer J.P., Christiani D.C., Wei Y., Shen H., Hu Z., Shu X.O., Shiraishi K., Takahashi A., Bosse Y., Obeidat M., Nickle D., Timens W., Free-dman M.L., Li Q., Seminara D., Chanock S.J., Gong J., Peters U., Gruber S.B., Amos C.I., Sellers T.A., Easton D.F., Hunter D.J., Haiman C.A., Henderson B.E., and Hung R.J. Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Co-lorectal Cancer Reveals Novel Pleiotropic Associa-tions. [2016] Cancer Research (76) 17 : 5103-5114.

108. Fend L., Remy-Ziller C., Foloppe J., Kempf J., Cochin S., Barraud L., Accart N., Erbs P., Fournel S., and Préville X. Oncolytic virotherapy with an ar-med vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tu-mor microenvironment. [2016] Oncoimmunology (5) 2 : e1080414.

109. Figueroa J.D., Middlebrooks C.D., Ban-day A.R., Ye Y., Garcia-Closas M., Chatterjee N., Koutros S., Kiemeney L.A., Rafnar T., Bishop T., Furberg H., Matullo G., Golka K., Gago-Domin-guez M., Taylor J.A., Fletcher T., Siddiq A., Cor-tessis V.K., Kooperberg C., Cussenot O., Benha-mou S., Prescott J., Porru S., Dinney C.P., Malats N., Baris D., Purdue M.P., Jacobs E.J., Albanes D., Wang Z., Chung C.C., Vermeulen S.H., Aben K.K., Galesloot T.E., Thorleifsson G., Sulem P., Stefansson K., Kiltie A.E., Harland M., Teo M., Offit K., Vijai J., Bajorin D., Kopp R., Fiorito G., Guarrera S., Sacerdote C., Selinski S., Hengstler J.G., Gerullis H., Ovsiannikov D., Blaszkewicz M., Castelao J.E., Calaza M., Martinez M.E., Cordeiro P., Xu Z., Panduri V., Kumar R., Gurzau E., Kop-pova K., Bueno-De-Mesquita H.B., Ljungberg B., Clavel-Chapelon F., Weiderpass E., Krogh V., Dorronsoro M., Travis R.C., Tjonneland A., Brennan P., Chang-Claude J., Riboli E., Conti D., Stern M.C., Pike M.C., Van Den Berg D., Yuan J.M., Hohensee C., Jeppson R.P., Cancel-Tassin G., Roupret M., Comperat E., Turman C., De Vivo I., Giovannucci E., Hunter D.J., Kraft P., Lindstrom S., Carta A., Pavanello S., Arici C., Mastrangelo G., Kamat A.M., Zhang L., Gong Y., Pu X., Hutchin-son A., Burdett L., Wheeler W.A., Karagas M.R., Johnson A., Schned A., Monawar Hosain G.M., Schwenn M., Kogevinas M., Tardon A., Serra C., Carrato A., Garcia-Closas R., Lloreta J., Andriole G., Jr., Grubb R., III, Black A., Diver W.R., Gapstur S.M., Weinstein S., Virtamo J., Haiman C.A., Lan-di M.T., Caporaso N.E., Fraumeni J.F., Jr., Vineis P., Wu X., Chanock S.J., Silverman D.T., Prokuni-na-Olsson L., and Rothman N. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus as-sociated with bladder cancer risk in individuals of European ancestry. [2016] Human Molecular Gene-tics (25) 6 : 1203-1214.

110. Fizazi K. Biennial report on genitourinary can-cers. [2016] European Journal of Cancer (66) : 125-130.

111. Fizazi K., Flaig T.W., Stockle M., Scher H.I., De Bono J.S., Rathkopf D.E., Ryan C.J., Kheoh T., Li J., Todd M.B., Griffin T.W., Molina A., and Ohlmann C.H. Does Gleason score at initial diagnosis predict effi-cacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. [2016] Annals of Oncology (27) 4 : 699-705.

112. Fossard G., Blond E., Balsat M., Morisset S., Giraudier S., Escoffre-Barbe M., Labussiere-Wal-let H., Heiblig M., Bert A., Etienne M., Drai J., Sobh M., Redonnet-Vernhet I., Lega J.C., Mahon F.X., Etienne G., and Nicolini F.E. Hyperhomocysteine-mia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leuke-mia patients. [2016] Haematologica (101) 3 : e86-e90.

113. Foulon S., Brennan B., Gaspar N., Dirksen U., Jeys L., Cassoni A., Claude L., Seddon B., Marec-Berard P., Whelan J., Paulussen M., Streit-buerger A., Oberlin O., Juergens H., Grimer R., and Le Deley M.C. Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group. [2016] European Journal of Cancer (61) : 128-136.

114. Frappaz D., Federico S.M., Pearson A.D., Gore L., Macy M.E., Dubois S.G., Aerts I., Iannone R., Geschwindt R., Van Schanke A., Wang R., and Geoerger B. Phase 1 study of dalotuzumab mono-therapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tu-mours. [2016] European Journal of Cancer (62) : 9-17.

115. Fu Y., Jovelet C., Filleron T., Pedrero M., Motte N., Boursin Y., Luo Y., Massard C., Campone M., Levy C., Dieras V., Bachelot T., Garrabey J., Soria J.C., Lacroix L., Andre F., and Lefebvre C. Improving the performance of somatic mutation identification by recovering circulating tumor DNA mutations. [2016] Cancer Research (76) 20 : 5954-5961. 116. Fucikova J., Becht E., Iribarren K., Goc J., Re-mark R., Damotte D., Alifano M., Devi P., Biton J., Germain C., Lupo A., Fridman W.H., Dieu-Nosjean M.C., Kroemer G., Sautes-Fridman C., and Cremer I. Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumula-tion of Antitumor Immune Cells and Favorable Pro-gnosis. [2016] Cancer Research (76) 7 : 1746-1756.

117. Fuerea A., Baciarello G., Patrikidou A., Albiges L., Massard C., Di Palma M., Escudier B., Fizazi K., and Loriot Y. Early PSA response is an independent prognostic factor in patients with metastatic castra-tion-resistant prostate cancer treated with next-ge-neration androgen pathway inhibitors. [2016] Euro-pean Journal of Cancer (61) : 44-51.

118. Fujiwara K., Monk B.J., Lhomme C., Coleman R.L., Brize A., Oaknin A., Ray-Coquard I., Fabbro M., Provencher D., Bamias A., Vergote I., DeCensi A., Zhang K., Vogl F.D., Bach B.A., and Raspagliesi F. Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1). [2016] Annals of Oncology (27) 6 : 1006-1013.

119. Fumagalli D., Wilson T.R., Salgado R., Lu X., Yu J., O’Brien C., Walter K., Huw L.Y., Criscitiello C., Laios I., Jose V., Brown D.N., Rothe F., Maetens M., Zardavas D., Savas P., Larsimont D., Piccart-Ge-bhart M.J., Michiels S., Lackner M.R., Sotiriou C., and Loi S. Somatic mutation, copy number and transcriptomic profiles of primary and matched me-tastatic estrogen receptor-positive breast cancers. [2016] Annals of Oncology (27) 10 : 1860-1866.

120. Gallo V., Vanacore N., Bueno-de-Mesquita H., Vermeulen R., Brayne C., Pearce N., Wark P.A., Ward H.A., Ferrari P., Jenab M., Andersen P.M., Wennberg P., Wareham N., Katzke V., Kaaks R., Weiderpass E., Peeters P.H., Mattiello A., Pala V., Barricante A., Chirlaque M.D., Travier N., Travis R.C., Sanchez M.J., Pessah-Rasmussen H., Peters-son J., Tjonneland A., Tumino R., Ramon Quiros

J., Trichopoulou A., Kyrozis A., Oikonomidou D., Masala G., Sacerdote C., Arriola L., Boeing H., Vigl M., Claver-Chapelon F., Middleton L., Riboli E., and Vineis P. Physical activity and risk of Amyotrophic Lateral Sclerosis in a prospective cohort study. [2016] European Journal of Epidemiology (31) 3 : 255-266.

121. Galluzzi L. and Kroemer G. Amino acid depriva-tion promotes intestinal homeostasis through auto-phagy. [2016] Oncotarget (7) 21 : 29877-29878. 122. Galluzzi L., Eggermont A., and Kroemer G. Doubling the blockade for melanoma immunothe-rapy. [2016] Oncoimmunology (5) 1 : e1106127. 123. Galluzzi L., Zitvogel L., and Kroemer G. Immu-nological Mechanisms Underneath the Efficacy of Cancer Therapy. [2016] Cancer Immunology Research (4) 11 : 895-902.

124. Galluzzi L., Bravo-San Pedro J.M., Kepp O., and Kroemer G. Regulated cell death and adaptive stress responses. [2016] Cellular and Molecular Life Sciences (73) 11-12 : 2405-2410.

125. Garbe C., Peris K., Hauschild A., Saiag P., Middleton M., Bastholt L., Grob J.J., Malvehy J., Newton-Bishop J., Stratigos A.J., Pehamberger H., and Eggermont A.M. Diagnosis and treatment of melanoma. European consensus-based interdis-ciplinary guideline - Update 2016. [2016] European Journal of Cancer (63) : 201-217. 126. Gingras I., Sonnenblick A., De Azambuja E., Paesmans M., Delaloge S., Aftimos P., Piccart M.J., Sotiriou C., Ignatiadis M., and Azim H.A., Jr. The current use and attitudes towards tumor genome sequencing in breast cancer. [2016] Scientific Reports (6) : 22517.

127. Girard P. and Seguin-Givelet A. Adjuvant Che-motherapy, Retrospective Cohorts, and the Immor-tal Time Bias. [2016] Journal of Thoracic Oncology (11) 11 : e144.

128. Giraud-Baro E., Dassa D., de Vathaire F., Garay R.P., and Obeid J. Schizophrenia-spectrum patients treated with long-acting injectable risperidone in real-life clinical settings: functional recovery in re-mitted versus stable, non-remitted patients (the EVe-REST prospective observational cohort study). [2016] BMC Psychiatry (16) : 8.

129. Gizzi M., Oberic L., Massard C., Poterie A., Gwenael L.T., Loriot Y., Albiges L., Baciarello G., Michels J., Bossi A., Blanchard P., Escudier B., and Fizazi K. Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemo-therapy for germ cell tumours. [2016] European Jour-nal of Cancer (69) : 151-157.

130. Graff J.N., Baciarello G., Armstrong A.J., Hi-gano C.S., Iversen P., Flaig T.W., Forer D., Parli T., Phung D., Tombal B., Beer T.M., and Sternberg C.N. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. [2016] Annals of Oncology (27) 2 : 286-294.

131. Green H., Hasmats J., Kupershmidt I., Eds-gard D., de Petris L., Lewensohn R., Blackhall F., Vikingsson S., Besse B., Lindgren A., Branden E., Koyi H., Peterson C., and Lundeberg J. Using Whole-Exome Sequencing to Identify Genetic Mar-kers for Carboplatin and Gemcitabine-Induced Toxi-cities. [2016] Clinical Cancer Research (22) 2 : 366-373.

132. Grin I. and Ishchenko A.A. An interplay of the base excision repair and mismatch repair pathways in active DNA demethylation. [2016] Nucleic Acids Re-search (44) 8 : 3713-3727.

133. Gronchi A., Strauss D.C., Miceli R., Bonvalot S., Swallow C.J., Hohenberger P., van Coevorden F., Rutkowski P., Callegaro D., Hayes A.J., Honore C., Fairweather M., Cannell A., Jakob J., Haas R.L., Szacht M., Fiore M., Casali P.G., Pollock R.E., and Raut C.P. Variability in Patterns of Recurrence Af-ter Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-ins-

titutional Collaborative RPS Working Group. [2016] Annals of Surgery (263) 5 : 1002-1009.

134. Guibert N., Pradines A., Casanova A., Farella M., Keller L., Soria J.C., Favre G., and Mazieres J. Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma. [2016] Jour-nal of Thoracic Oncology (11) 9 : e109-e112.

135. Guirouilh-Barbat J., Gelot C., Xie A., Dardillac E., Scully R., and Lopez B.S. 53BP1 Protects against CtIP-Dependent Capture of Ectopic Chromosomal Sequences at the Junction of Distant Double-Strand Breaks. [2016] PLoS Genetics (12) 10 : e1006230. 136. Hacker E., Olsen C.M., Kvaskoff M., Pandeya N., Yeo A., Green A.C., Williamson R.M., Triscott J., Wood D., Mortimore R., Hayward N.K., and White-man D.C. Histologic and Phenotypic Factors and MC1R Status Associated with BRAF(V600E), BRAF(V600K), and NRAS Mutations in a Community-Based Sample of 414 Cutaneous Melanomas. [2016] Journal of Investi-gative Dermatology (136) 4 : 829-837.

137. Hagemeyer N., Kierdorf K., Frenzel K., Xue J., Ringelhan M., Abdullah Z., Godin I., Wieghofer P., Costa Jordao M.J., Ulas T., Yorgancioglu G., Rosen-bauer F., Knolle P.A., Heikenwalder M., Schultze J.L., and Prinz M. Transcriptome-based profiling of yolk sac-derived macrophages reveals a role for Irf8 in macrophage maturation. [2016] EMBO Journal (35) 16 : 1730-1744.

138. Hallet J., Sa C.A., Adam R., Goere D., Bachellier P., Azoulay D., Ayav A., Gregoire E., Navarro F., and Pessaux P. Factors influencing recurrence following initial hepatectomy for colorectal liver metastases. [2016] British Journal of Surgery (103) 10 : 1366-1376.

139. Hamel J.F., Pe M., Coens C., Martinelli F., Eggermont A.M., Brandberg Y., and Bottomley A. A systematic review examining factors influen-cing health related quality of life among melanoma cancer survivors. [2016] European Journal of Cancer (69) : 189-198.

140. Harbeck N., Iyer S., Turner N., Cristofanilli M., Ro J., Andre F., Loi S., Verma S., Iwata H., Bhatta-charyya H., Puyana T.K., Bartlett C.H., and Loibl S. Quality of life with palbociclib plus fulvestrant in pre-viously treated hormone receptor-positive, HER2-ne-gative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. [2016] Annals of Oncology (27) 6 : 1047-1054.

141. Hasmim M., Bruno S., Azzi S., Gallerne C., Michel J.G., Chiabotto G., Lecoz V., Romei C., Spag-giari G.M., Pezzolo A., Pistoia V., Angevin E., Gad S., Ferlicot S., Messai Y., Kieda C., Clay D., Sabatini F., Escudier B., Camussi G., Eid P., Azzarone B., and Chouaib S. Isolation and characterization of renal cancer stem cells from patient-derived xenografts. [2016] Oncotarget (7) 13 : 15507-15524.

142. Helissey C., Biondani P., Roquet F., Lanoy E., Mir O., Varga A., Massard C., Gazzah A., Ribrag V., Bahleda R., Postel-Vinay S., Angevin E., Deutsch E., Soria J.C., and Hollebecque A. Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience. [2016] International Journal of Cancer (138) 4 : 875-880.

143. Hernandez-Perez S., Cabrera E., Amoedo H., Rodriguez-Acebes S., Koundrioukoff S., Debatisse M., Mendez J., and Freire R. USP37 deubiquitinates Cdt1 and contributes to regulate DNA replication. [2016] Molecular Oncology (10) 8 : 1196-1206.

144. His M., Fagherazzi G., Mesrine S., Bou-tron-Ruault M.C., Clavel-Chapelon F., and Dossus L. Prediagnostic body size and breast cancer survival in the E3N cohort study. [2016] International Journal of Cancer (139) 5 : 1053-1064.

145. Houot R., Pachynski R., Czerwinski D.K., Goldstein M.J., Sagiv-Barfi I., Brody J., Muller A.M., and Marabelle A. Holbrook Kohrt: In Memoriam (1977-2016). [2016] Clinical Cancer Research (22) 14 : 3695-3696.

146. Houot R., Gaulard P., Schreiber R., Mellman I., Lambotte O., Coulie P.G., Fest T., Korman A., Levy R., Shipp M., Tarte K., Kohrt H., Marabelle A., An-sell S., Watier H., van Elsas A., Balakumaran A., Arce Vargas F., Quezada S.A., Salles G., and Olive D. Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. [2016] Oncoimmunology (5) 7 : e1186323.

147. Houvenaeghel G., Sabatier R., Reyal F., Classe J.M., Giard S., Charitansky H., Rouzier R., Faure C., Garbay J.R., Darai E., Hudry D., Gimbergues P., Villet R., and Lambaudie E. Axillary lymph node mi-crometastases decrease triple-negative early breast cancer survival. [2016] British Journal of Cancer (115) 9 : 1024-1031.

148. Houvenaeghel G., Boher J.M., Reyal F., Cohen M., Garbay J.R., Classe J.M., Rouzier R., Giard S., Faure C., Charitansky H., Tunon de L.C., Darai E., Hudry D., Azuar P., Gimbergues P., Villet R., Sfuma-to P., and Lambaudie E. Impact of completion axillary lymph node dissection in patients with breast cancer and isolated tumour cells or micrometastases in sen-tinel nodes. [2016] European Journal of Cancer (67) : 106-118.

149. Houvenaeghel G., Classe J.M., Garbay J.R., Giard S., Cohen M., Faure C., Charytansky H., Rou-zier R., Darai E., Hudry D., Azuar P., Villet R., Gim-bergues P., de Lara C.T., Martino M., Fraisse J., Dravet F., Chauvet M.P., Goncalves A., and Lambau-die E. Survival impact and predictive factors of axilla-ry recurrence after sentinel biopsy. [2016] European Journal of Cancer (58) : 73-82.

150. Hua C., Boussemart L., Mateus C., Routier E., Boutros C., Cazenave H., Viollet R., Thomas M., Roy S., Benannoune N., Tomasic G., Soria J.C., Champiat S., Texier M., Lanoy E., and Robert C. Association of Vitiligo With Tumor Response in Patients With Metas-tatic Melanoma Treated With Pembrolizumab. [2016] JAMA Dermatology (152) 1 : 45-51.

151. Hughes D.J., Duarte-Salles T., Hybsier S., Tri-chopoulou A., Stepien M., Aleksandrova K., Over-vad K., Tjonneland A., Olsen A., Affret A., Faghe-razzi G., Boutron-Ruault M.C., Katzke V., Kaaks R., Boeing H., Bamia C., Lagiou P., Peppa E., Palli D., Krogh V., Panico S., Tumino R., Sacerdote C., Bueno-De-Mesquita H.B., Peeters P.H., Engeset D., Weiderpass E., Lasheras C., Agudo A., Sanchez M.J., Navarro C., Ardanaz E., Dorronsoro M., Hem-mingsson O., Wareham N.J., Khaw K.T., Bradbury K.E., Cross A.J., Gunter M., Riboli E., Romieu I., Schomburg L., and Jenab M. Prediagnostic sele-nium status and hepatobiliary cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. [2016] American Journal of Clinical Nutrition (104) 2 : 406-414 .

152. Husing A., Dossus L., Ferrari P., Tjonneland A., Hansen L., Fagherazzi G., Baglietto L., Schock H., Chang-Claude J., Boeing H., Steffen A., Tricho-poulou A., Bamia C., Katsoulis M., Krogh V., Palli D., Panico S., Onland-Moret N.C., Peeters P.H., Bueno-De-Mesquita H.B., Weiderpass E., Gram I.T., Ardanaz E., Obon-Santacana M., Navarro C., Sanchez-Cantalejo E., Etxezarreta N., Allen N.E., Khaw K.T., Wareham N., Rinaldi S., Romieu I., Merritt M.A., Gunter M., Riboli E., and Kaaks R. An epidemiological model for prediction of endometrial cancer risk in Europe. [2016] European Journal of Epi-demiology (31) 1 : 51-60.

153. Infante J.R., Cassier P.A., Gerecitano J.F., Wit-teveen P.O., Chugh R., Ribrag V., Chakraborty A., Matano A., Dobson J.R., Crystal A.S., Parasuraman S., and Shapiro G.I. A Phase I Study of the Cyclin-De-pendent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients With Advanced Solid Tumors and Lympho-mas. [2016] Clinical Cancer Research (22) 23 : 5696-5705. 154. Iribarren K., Bloy N., Buque A., Cremer I., Eg-germont A., Fridman W.H., Fucikova J., Galon J., Spisek R., Zitvogel L., Kroemer G., and Galluzzi L. Trial Watch - Immunostimulation with Toll-like re-ceptor agonists in cancer therapy. [2016] Oncoimmu-nology (5) 3 : e1088631.

155. Jacquelot N., Roberti M.P., Enot D.P., Rusa-kiewicz S., Semeraro M., Jegou S., Flores C., Chen L., Kwon B.S., Borg C., Weide B., Aubin F., Dalle S., Kohrt H., Ayyoub M., Kroemer G., Marabelle A., Cavalcanti A., Eggermont A., and Zitvogel L. Immu-nophenotyping of Stage III Melanoma Reveals Pa-rameters Associated with Patient Prognosis. [2016] Journal of Investigative Dermatology (136) 5 : 994-1001.

156. Janji B., Viry E., Moussay E., Paggetti J., Ara-kelian T., Mgrditchian T., Messai Y., Noman M.Z., Van Moer K., Hasmim M., Mami-Chouaib F., Ber-chem G., and Chouaib S. The multifaceted role of au-tophagy in tumor evasion from immune surveillance. [2016] Oncotarget (7) 14 : 17591-17607.

157. Jemaa M., Manic G., Lledo G., Lissa D., Reynes C., Morin N., Chibon F., Sistigu A., Castedo M., Vi-tale I., Kroemer G., and Abrieu A. Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition. [2016] Oncotarget (7) 1 : 885-901.

158. Joly A.L., Deepti A., Seignez A., Goloudina A., Hebrard S., Schmitt E., Richaud S., Fourmaux E., Hammann A., Collura A., Svrcek M., Jego G., Robi-net E., Solary E., Demidov O., Kohli E., and Garrido C. The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development. [2016] Oncogene (35) 22 : 2842-2851.

159. Jorgov L., Montravers F., Balogova S., Ragu C., Pacquement H., Leblanc T., Abbou S., Du-cou-Lepointe H., Landman-Parker J., and Talbot J.N. Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on inte-rim PET/CT. [2016] European Journal of Nuclear Medi-cine and Molecular Imaging (43) 7 : 1220-1230.

160. Jovelet C., Ileana E., Le Deley M.C., Motte N., Rosellini S., Romero A., Lefebvre C., Pedrero M., Pata-Merci N., Droin N., Deloger M., Massard C., Hollebecque A., Ferte C., Boichard A., Postel-Vinay S., Ngo-Camus M., de Baere T., Vielh P., Scoazec J.Y., Vassal G., Eggermont A., Andre F., Soria J.C., and Lacroix L. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. [2016] Clinical Can-cer Research (22) 12 : 2960-2968.

161. Karlovich C., Goldman J.W., Sun J.M., Mann E., Sequist L.V., Konopa K., Wen W., Angenendt P., Horn L., Spigel D., Soria J.C., Solomon B., Camidge D., Gadgeel S., Paweletz C., Wu L., Chien S., O’Don-nell P., Matheny S., Despain D., Rolfe L., Raponi M., Allen A.R., Park K., and Wakelee H. Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Ro-ciletinib (CO-1686). [2016] Clinical Cancer Research (22) 10 : 2386-2395.

162. Kaymakcalan M.D., Xie W., Albiges L., Nor-th S.A., Kollmannsberger C.K., Smoragiewicz M., Kroeger N., Wells J.C., Rha S.Y., Lee J.L., Mc-kay R.R., Fay A.P., De Velasco G., Heng D.Y., and Choueiri T.K. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. [2016] Cancer (122) 3 : 411-419.

163. Kepenekian V., Elias D., Passot G., Mery E., Goere D., Delroeux D., Quenet F., Ferron G., Pezet D., Guilloit J.M., Meeus P., Pocard M., Bereder J.M., Abboud K., Arvieux C., Brigand C., Marchal F., Classe J.M., Lorimier G., de Chaisemartin C., Guyon F., Mariani P., Ortega-Deballon P., Isaac S., Maurice C., Gilly F.N., and Glehen O. Diffuse malignant peri-toneal mesothelioma: Evaluation of systemic chemo-therapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. [2016] European Journal of Cancer (65) : 69-79.

164. Kleinpeter P., Fend L., Thioudellet C., Geist M., Sfrontato N., Koerper V., Fahrner C., Schmitt D., Gantzer M., Remy-Ziller C., Brandely R., Villeval D., Rittner K., Silvestre N., Erbs P., Zitvogel L., Queme-neur E., Preville X., and Marchand J.B. Vectorization

in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. [2016] Oncoimmunology (5) 10 : e1220467.

165. Klionsky D.J.e.al., Bravo-San Pedro J.M., Gal-luzzi L., Izzo V., Pietrocola F., Sica V., Deutsch E., Dokudovskaya S., and Kroemer G. Guidelines for the use and interpretation of assays for monitoring au-tophagy (3rd edition). [2016] Autophagy (12) 1 : 1-222.

166. Kouidhi S., Noman M.Z., Kieda C., Elgaaied A.B., and Chouaib S. Intrinsic and Tumor Microenvi-ronment-Induced Metabolism Adaptations of T Cells and Impact on Their Differentiation and Function. [2016] Frontiers in Immunology (7) : 114. 167. Kowalczyk J.R., Samardakiewicz M., Prit-chard-Jones K., Ladenstein R., Essiaf S., Fitzgerald E., Petrarulo G., and Vassal G. European Survey on Standards of Care in paediatric oncology centres. [2016] European Journal of Cancer (61) : 11-19.

168. Krishnan K., Baglietto L., Apicella C., Stone J., Southey M.C., English D.R., Giles G.G., and Hopper J.L. Mammographic density and risk of breast cancer by mode of detection and tumor size: a case-control study. [2016] Breast Cancer Research (18) 1 : 63.

169. Kroemer G. Dying cell recognition shapes the pathophysiology of cell death. [2016] Cell Death & Differentiation (23) 6 : 913-914.

170. Kroemer G., Galluzzi L., and Zitvogel L. STAT3 inhibition for cancer therapy: Cell-autonomous ef-fects only? [2016] Oncoimmunology (5) 5 : e1126063.

171. Kwiatkowski D.J., Choueiri T.K., Fay A.P., Rini B.I., Thorner A.R., de Velasco G., Tyburczy M.E., Hamieh L., Albiges L., Agarwal N., Ho T.H., Song J., Pignon J.C., Barrios P.M., Michaelson M., Van Allen E.M., Krajewski K.M., Porta C., Pal S.K., Bellmunt J., McDermott D.F., Heng D.Y., Gray K.P., and Signo-retti S. Mutations in TSC1, TSC2, and MTOR Are As-sociated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. [2016] Clinical Can-cer Research (22) 10 : 2445-2452. 172. Labrize F., Cany L., Massard C., Loriot Y., Sargos P., Gross-Goupil M., and Roubaud G. Enzalutamide and sleep apnea: An emerging central nervous system side-effect? [2016] Annals of Oncology (27) 1 : 206. 173. Ladoire S., Senovilla L., Enot D., Ghiringhelli F., Poirier-Colame V., Chaba K., Erdag G., Schaefer J.T., Deacon D.H., Zitvogel L., Slingluff C.L., Jr., and Kroemer G. Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate. [2016] Oncoimmunology (5) 6 : e1160193.

174. Ladoire S., Enot D., Andre F., Zitvogel L., and Kroemer G. Immunogenic cell death-related bio-markers: Impact on the survival of breast cancer patients after adjuvant chemotherapy. [2016] Oncoim-munology (5) 2 : e1082706.

175. Ladoire S., Enot D., Senovilla L., Chaix M., Zitvo-gel L., and Kroemer G. Positive impact of autophagy in human breast cancer cells on local immunosurveil-lance. [2016] Oncoimmunology (5) 6 : e1174801.

176. Ladoire S., Enot D., Senovilla L., Ghiringhel-li F., Poirier-Colame V., Chaba K., Semeraro M., Chaix M., Penault-Llorca F., Arnould L., Poillot M.L., Arveux P., Delaloge S., Andre F., Zitvogel L., and Kroemer G. The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. [2016] Auto-phagy (12) 5 : 864-875.

177. Lae M., Gardrat S., Rondeau S., Richardot C., Caly M., Chemlali W., Vacher S., Couturier J., Ma-riani O., Terrier P., and Bieche I. MED12 mutations in breast phyllodes tumors: evidence of temporal tu-moral heterogeneity and identification of associated critical signaling pathways. [2016] Oncotarget (7) 51 : 84428-84438.

178. Lajous M., Rossignol E., Fagherazzi G., Per-quier F., Scalbert A., Clavel-Chapelon F., and Boutron-Ruault M.C. Flavonoid intake and incident hypertension in women. [2016] American Journal of Clinical Nutrition (103) 4 : 1091-1098.

179. Lakisic G., Lebreton A., Pourpre R., Wendling O., Libertini E., Radford E.J., Le Guillou M., Champy M.F., Wattenhofer-Donze M., Soubigou G., Ait-Si-Ali S., Feunteun J., Sorg T., Coppee J.Y., Fergu-son-Smith A.C., Cossart P., and Bierne H. Role of the BAHD1 Chromatin-Repressive Complex in Placental Development and Regulation of Steroid Metabolism. [2016] PLoS Genetics (12) 3 : e1005898.

180. Lamartina L., Ippolito S., Danis M., Bidault F., Borget I., Berdelou A., Al Ghuzlan A., Hartl D., Blanchard P., Terroir M., Deandreis D., Schlumber-ger M., Baudin E., and Leboulleux S. Antiangiogenic Tyrosine Kinase Inhibitors: occurrence and risk fac-tors of hemoptysis in refractory thyroid cancer. [2016] Journal of Clinical Endocrinology & Metabolism (101) 7 : 2733-2741. 181. Lassalle S., Zangari J., Popa A., Ilie M., Hof-man V., Long E., Patey M., Tissier F., Belleannee G., Trouette H., Catargi B., Peyrottes I., Sadoul J.L., Bordone O., Bonnetaud C., Butori C., Bozec A., Gue-vara N., Santini J., Henaoui I.S., Lemaire G., Blank O., Vielh P., Barbry P., Mari B., Brest P., and Hofman P. MicroRNA-375/SEC23A as biomarkers of the in vi-tro efficacy of vandetanib. [2016] Oncotarget (7) 21 : 30461-30478.

182. Lassau N., Coiffier B., Kind M., Vilgrain V., Lacroix J., Cuinet M., Taieb S., Aziza R., Sarran A., Labbe-Devilliers C., Gallix B., Lucidarme O., Ptak Y., Rocher L., Caquot L.M., Chagnon S., Marion D., Luciani A., Feutray S., Uzan-Augui J., Benatsou B., Bonastre J., and Koscielny S. Selection of an early biomarker for vascular nor-malization using dynamic contrast-enhanced ul-trasonography to predict outcomes of metastatic patients treated with bevacizumab. [2016] Annals of Oncology (27) 10 : 1922-1928.

183. Laurent C., Fabiani B., Do C., Tchernonog E., Cartron G., Gravelle P., Amara N., Malot S., Palisoc M.M., Copie-Bergman C., Glehen A.T., Copin M.C., Brousset P., Pittaluga S., Jaffe E.S., and Coppo P. Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients. [2016] Haematologica (101) 8 : 976-984.

184. Le Besnerais M., Favre J., Denis C.V., Mul-der P., Martinet J., Nicol L., Levesque H., Veyra-dier A., Kopic A., Motto D.G., Coppo P., Richard V., and Benhamou Y. Assessment of endothelial damage and cardiac injury in a mouse model mi-micking thrombotic thrombocytopenic purpura. [2016] Journal of Thrombosis and Haemostasis (14) 10 : 1917-1930. 185. Le Roy A., Kempf E., Ackermann F., Routier E., Robert C., Turpin A., Marabelle A., Mateus C., Michot J.M., and Lambotte O. Two cases of immune thrombocytopenia associated with pembrolizumab. [2016] European Journal of Cancer (54) : 172-174.

186. Lebellec L., Bertucci F., Tresch-Bruneel E., Bompas E., Toiron Y., Camoin L., Mir O., Laurence V., Clisant S., Decoupigny E., Blay J.Y., Goncalves A., and Penel N. Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafe-nib: an analysis from a phase II trial of the french sar-coma group (GSF/GETO). [2016] Oncotarget (7) 45 : 73984.

187. Lemonnier F., Cairns R.A., Inoue S., Li W.Y., Dupuy A., Broutin S., Martin N., Fataccioli V., Pelle-tier R., Wakeham A., Snow B.E., de Leval L., Pujals A., Haioun C., Paci A., Tobin E.R., Narayanaswamy R., Yen K., Jin S., Gaulard P., and Mak T.W. The IDH2 R172K mutation associated with angioimmunoblas-tic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. [2016] Proceedings of the National Academy of Sciences of the United States of America (113) 52 : 15084-15089.

188. Lerebours F., Rivera S., Mouret-Reynier M.A., Alran S., Venat-Bouvet L., Kerbrat P., Salmon R., Becette V., Bourgier C., Cherel P., Boussion V., Bal-leyguier C., Thibault F., Lavau-Denes S., Nabholz J.M., Sigal B., Trassard M., Mathieu M.C., Martin A.L., Lemonnier J., and Mouret-Fourme E. Ran-domized phase 2 neoadjuvant trial evaluating anas-trozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609). [2016] Cancer (122) 19 : 3032-3040.

189. Lesluyes T., Perot G., Largeau M.R., Brulard C., Lagarde P., Dapremont V., Lucchesi C., Neuville A., Ter-rier P., Vince-Ranchere D., Mendez-Lago M., Gut M., Gut I., Coindre J.M., and Chibon F. RNA sequencing vali-dation of the Complexity INdex in SARComas prognostic signature. [2016] European Journal of Cancer (57) : 104-111.

190. Lesueur L.L., Mir L.M., and Andre F.M. Over-coming the Specific Toxicity of Large Plasmids Elec-trotransfer in Primary Cells In Vitro. [2016] Molecular Therapy-Nucleic Acids (5) : e291.

191. Levi F.A., Boige V., Hebbar M., Smith D., Le-pere C., Focan C., Karaboue A., Guimbaud R., Carval-ho C., Tumolo S., Innominato P., Ajavon Y., Truant S., Castaing D., de Baere T., Kunstlinger F., Bouchahda M., Afshar M., Rougier P., Adam R., and Ducreux M. Conversion to resection of liver metastases from co-lorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. [2016] Annals of Oncology (27) 2 : 267-274.

192. Levy A., Chargari C., Marabelle A., Perfettini J.L., Magne N., and Deutsch E. Can immunostimula-tory agents enhance the abscopal effect of radiothe-rapy? [2016] European Journal of Cancer (62) : 36-45. 193. Levy A., Massard C., Soria J.C., and Deutsch E. Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalu-mab: Single centre subset analysis from a phase 1/2 trial. [2016] European Journal of Cancer (68) : 156-162.

194. Lipton A., Smith M.R., Fizazi K., Stopeck A.T., Henry D., Brown J., Shore N.D., Saad F., Spencer A., Zhu L., and Warner D.J. Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients With Advanced Cancer and Bone Metastases Treated With Bone Antiresorptive Agents. [2016] Clinical Can-cer Research (22) 23 : 5713-5721.

195. Lipton A., Fizazi K., Stopeck A.T., Henry D.H., Smith M.R., Shore N., Martin M., Vadhan-Raj S., Brown J.E., Richardson G.E., Saad F., Yardley D.A., Zhou K., Balakumaran A., and Braun A. Effect of de-nosumab versus zoledronic acid in preventing skele-tal-related events in patients with bone metastases by baseline characteristics. [2016] European Journal of Cancer (53) : 75-83.

196. Loganadane G., Martinetti F., Mercier O., Krhili S., Riet F.G., Mbagui R., To H., Le Pechoux C., and Levy A. Ste-reotactic ablative radiotherapy for early stage non-small cell lung cancer: A critical literature review of predictive factors of relapse. [2016] Cancer Treatment Reviews (50) : 240-246.

197. Lokerse W.J., Bolkestein M., ten Hagen T.L., De Jong M., Eggermont A.M., Grull H., and Koning G.A. Investigation of Particle Accumulation, Chemosensi-tivity and Thermosensitivity for Effective Solid Tumor Therapy Using Thermosensitive Liposomes and Hy-perthermia. [2016] Theranostics (6) 10 : 1717-1731.

198. Lokerse W.J., Kneepkens E.C., ten Hagen T.L., Eggermont A.M., Grull H., and Koning G.A. In depth study on thermosensitive liposomes: Optimizing for-mulations for tumor specific therapy and in vitro to in vivo relations. [2016] Biomaterials (82) : 138-150. 199. Long G.V., Atkinson V., Ascierto P.A., Robert C., Hassel J.C., Rutkowski P., Savage K.J., Tay-lor F., Coon C., Gilloteau I., Dastani H.B., Waxman I.M., and Abernethy A.P. Effect of nivolumab on health-related quality of life in patients with treat-ment-naive advanced melanoma: results from the phase III CheckMate 066 study. [2016] Annals of Onco-logy (27) 10 : 1940-1946.

200. Lutz M.P., Zalcberg J.R., Glynne-Jones R., Ruers T., Ducreux M., Arnold D., Aust D., Brown G., Bujko K., Cunningham C., Evrard S., Folprecht G., Gerard J.P., Habr-Gama A., Haustermans K., Holm T., Kuhlmann K.F., Lordick F., Mentha G., Moehler M., Nagtegaal I.D., Pigazzi A., Puciarelli S., Roth A., Rutten H., Schmoll H.J., Sorbye H., Van Cutsem E., Weitz J., and Otto F. Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer. [2016] European Journal of Cancer (63) : 11-24.

201. Ly N., Elkhatib N., Bresteau E., Pietrement O., Khaled M., Magiera M.M., Janke C., Le cam E., Rutenberg A.D., and Montagnac G. alphaTAT1 controls longitudinal spreading of acetylation marks from open microtubules extremities. [2016] Scientific Reports (6) : 35624.

202. Ma X., Le Teuff G., Lacas B., Tsao M.S., Gra-ziano S., Pignon J.P., Douillard J.Y., Le Chevalier T., Seymour L., Filipits M., Pirker R., Janne P.A., Shepherd F.A., Brambilla E., Soria J.C., and Hai-naut P. Prognostic and Predictive Effect of TP53 Mu-tations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis. [2016] Journal of Thoracic Oncology (11) 6 : 850-861.

203. Macari F., El-Houfi Y., Boldina G., Xu H., Khou-ry-Hanna S., Ollier J., Yazdani L., Zheng G., Bieche I., Legrand N., Paulet D., Durrieu S., Bystrom A., Delbecq S., Lapeyre B., Bauchet L., Pannequin J., Hollande F., Pan T., Teichmann M., Vagner S., David A., Choquet A., and Joubert D. TRM6/61 connects PKCa with translational control through tRNAi(Met) stabilization: impact on tumorigenesis. [2016] On-cogene (35) 14 : 1785-1796.

204. Mahfoudhi E., Lordier L., Marty C., Pan J., Roy A., Roy L., Rameau P., Abbes S., Debili N., Raslova H., Chang Y., Debussche L., Vainchenker W., and Plo I. P53 activation inhibits all types of hematopoie-tic progenitors and all stages of megakaryopoiesis. [2016] Oncotarget (7) 22 : 31980-31992.

205. Malbec O., Cassard L., Albanesi M., Jonsson F., Mancardi D., Chicanne G., Payrastre B., Dubreuil P., Vivier E., and DaEron M. Trans-inhibition of activation and proliferation signals by Fc receptors in mast cells and basophils. [2016] Science Signaling (9) 459 : ra126.

206. Manson G., Norwood J., Marabelle A., Kohrt H., and Houot R. Biomarkers associated with checkpoint inhibitors. [2016] Annals of Oncology (27) 7 : 1199-1208.

207. Marabelle A. and Houot R. A tribute to the life and career of Holbrook Kohrt. [2016] Annals of Onco-logy (27) 7 : 1183-1184.

208. Marabelle A., Routy B., Michels J., Kroemer G., and Zitvogel L. Prime time for immune-check-point targeted therapy at ASCO 2015. [2016] Oncoim-munology (5) 3 : e1068494.

209. Marguet S., Mazouni C., Ramaekers B.L.T., Dunant A., Kates R., Jacobs V.R., Joore M.A., Har-beck N., and Bonastre J. European cost-effective-ness study of uPA/PAI-1 biomarkers to guide adju-vant chemotherapy decisions in breast cancer. [2016] European Journal of Cancer (63) : 168-179.

210. Maria A.G., Dillenburg-Pilla P., Reis R.I., Flo-riano E.M., Tefe-Silva C., Ramos S.G., Pesquero J.B., Nahmias C., and Costa-Neto C.M. Host kinin B1 receptor plays a protective role against melanoma progression. [2016] Scientific Reports (6) : 22078.

211. Markt S.C., Lago-Hernandez C.A., Miller R.E., Mahal B.A., Bernard B., Albiges L., Frazier L.A., Beard C.J., Wright A.A., and Sweeney C.J. Insurance status and disparities in disease presentation, treat-ment, and outcomes for men with germ cell tumors. [2016] Cancer (122) 20 : 3127-3135.

212. Marthey L., Mateus C., Mussini C., Nachury M., Nancey S., Grange F., Zallot C., Peyrin-Biroulet L., Rahier J., de Beauregard M., Mortier L., Coutzac C.,

Soularue E., Lanoy E., Kapel N., Planchard D., Cha-put N., Robert C., and Carbonnel F. Cancer Immuno-therapy with Anti-CTLA-4 Monoclonal Antibodies In-duces an Inflammatory Bowel Disease. [2016] Journal of Crohns & Colitis (10) 4 : 395-401.

213. Massard C., Oulhen M., Le Moulec S., Auger N., Foulon S., Abou-Lovergne A., Billiot F., Valent A., Marty V., Loriot Y., Fizazi K., Vielh P., and Farace F. Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metasta-tic castrationresistant prostate cancer: a report from the PETRUS prospective study. [2016] Oncotarget (7) 34 : 55069-55082.

214. Masserot C., Liu Q., Nguyen E., Gattolliat C.H., Val-teau-Couanet D., Benard J., Huber C., and Segal-Ben-dirdjian E. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma. [2016] Molecular Oncology (10) 2 : 240-252.

215. Maurer M.J., Jais J.P., Ghesquieres H., Witzig T.E., Hong F., Haioun C., Thompson C.A., Thieble-mont C., Micallef I.N., Porrata L.F., Ribrag V., Nowa-kowski G.S., Casasnovas O., Bologna S., Morschhau-ser F., Morrison V.A., Peterson B.A., Macon W.R., Copie-Bergman C., Feldman A.L., Syrbu S.I., Kurtin P.J., Gascoyne R.D., Li H., Allmer C., Kahl B.S., Ansell S.M., Slager S.L., Link B.K., Salles G., Habermann T.M., Tilly H., and Cerhan J.R. Personalized risk pre-diction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. [2016] American Journal of Hematology (91) 2 : 179-184.

216. Mazières J., Barlesi F., Filleron T., Besse B., Monnet I., Beau-Faller M., Peters S., Dansin E., Früh M., Pless M., Rosell R., Wislez M., Fournel P., Westeel V., Cappuzzo F., Cortot A., Moro-Sibilot D., Milia J., and Gautschi O. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: Results from the European EU-HER2 cohort. [2016] Annals of Oncology (27) 2 : 281-286.

217. McGovern S., Baconnais S., Roblin P., Nicolas P., Drevet P., Simonson H., Pietrement O., Charbon-nier J.B., Le Cam E., Noirot P., and Lecointe F. C-ter-minal region of bacterial Ku controls DNA bridging, DNA threading and recruitment of DNA ligase D for double strand breaks repair. [2016] Nucleic Acids Re-search (44) 10 : 4785-4806.

218. Mckay R.R., Lin X., Albiges L., Fay A.P., Kay-makcalan M.D., Mickey S.S., Ghoroghchian P.P., Bhatt R.S., Kaffenberger S.D., Simantov R., Chouei-ri T.K., and Heng D.Y. Statins and survival outcomes in patients with metastatic renal cell carcinoma. [2016] European Journal of Cancer (52) : 155-162.

219. Mephon-Gaspard A., Boca M., Pioche-Durieu C., Desforges B., Burgo A., Hamon L., Pietrement O., and Pastre D. Role of tau in the spatial organiza-tion of axonal microtubules: keeping parallel micro-tubules evenly distributed despite macromolecular crowding. [2016] Cellular and Molecular Life Sciences (73) 19 : 3746-3760.

220. Merad M., Savale L., Antoun S., and Vincent F. Is there hope of improving the prognosis of pulmona-ry tumour thrombotic microangiopathy? [2016] Euro-pean Respiratory Journal (47) 2 : 688-690.

221. Merritt M.A., Tzoulaki J., van den Brandt P.A., Schouten L.J., Tsilidis K.K., Weiderpass E., Patel C.J., Tjonneland A., Hansen L., Overvad K., His M., Dartois L., Boutron-Ruault M.C., Fortner R.T., Kaaks R., Aleksandrova K., Boeing H., Trichopoulou A., Lagiou P., Bamia C., Palli D., Krogh V., Tumino R., Ricceri F., Mattiello A., Bueno-de-Mesquita H., Onland-Moret N., Peeters P.H., Skeie G., Jareid M., Quiros J.R., Obon-Santacana M., Sanchez M.J., Chamosa S., Huerta J.M., Barricarte A., Dias J.A., Sonestedt E., Idahl A., Lundin E., Wareham N.J., Khaw K.T., Travis R.C., Ferrari P., Riboli E., and Gunter M.J. Nutrient-wide association study of 57 foods/nutrients and epithelial ovarian cancer in the European Prospective Investigation into Cancer and Nutrition study and the Netherlands Cohort Study. [2016] American Journal of Clinical Nutrition (103) 1 : 161-167.

222. Messaoudene M., Fregni G., Enot D., Jacquelot N., Neves E., Germaud N., Garchon H.J., Boukoua-ci W., Tamouza R., Chanal J., Avril M.F., Toubert A., Zitvogel L., Rusakiewicz S., and Caignard A. NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution. [2016] Oncoimmunology (5) 12 : e1154251.

223. Messiou C., Bonvalot S., Gronchi A., Vanel D., Meyer M., Robinson P., Morosi C., Bloem J., Ter-rier P., Lazar A., Le Pechoux C., Wardelman E., Winfield J., Boulet B., Bovee J., and Haas R. Eva-luation of response after pre-operative radiothe-rapy in soft tissue sarcomas; the European Organi-sation for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC - STBSG) and Imaging Group recommendations for radiolo-gical examination and reporting with an emphasis on magnetic resonance imaging. [2016] European Journal of Cancer (56) : 37-44.

224. Michiels S., Pugliano L., Marguet S., Grun D., Barinoff J., Cameron D., Cobleigh M., Di L.A., Johnston S., Gasparini G., Kaufman B., Marty M., Nekljudova V., Paluch-Shimon S., Penault-Llorca F., Slamon D., Vogel C., von M.G., Buyse M., and Piccart M. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. [2016] Annals of Oncology (27) 6 : 1029-1034.

225. Michiels S., Ternes N., and Rotolo F. Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice. [2016] Annals of Oncology (27) 12 : 2160-2167.

226. Michot J.M., Mazeron R., Dercle L., Ammari S., Canova C., Marabelle A., Rose S., Rubin E., Deutsch E., Soria J.C., Ribrag V., and Levy A. Abscopal ef-fect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody. [2016] European Journal of Cancer (66) : 91-94.

227. Michot J.M., Bigenwald C., Champiat S., Col-lins M., Carbonnel F., Postel-Vinay S., Berdelou A., Varga A., Bahleda R., Hollebecque A., Massard C., Fuerea A., Ribrag V., Gazzah A., Armand J.P., Amellal N., Angevin E., Noel N., Boutros C., Ma-teus C., Robert C., Soria J.C., Marabelle A., and Lambotte O. Immune-related adverse events with immune checkpoint blockade: A comprehensive review. [2016] European Journal of Cancer (54) : 139-148.

228. Mir O., Broutin S., Perret A., Le Cesne A., and Paci A. Individualized Pazopanib Dosing-Letter. [2016] Clinical Cancer Research (22) 24 : 6298. 229. Missiroli S., Bonora M., Patergnani S., Poletti F., Perrone M., Gafa R., Magri E., Raimondi A., Lan-za G., Tacchetti C., Kroemer G., Pandolfi P.P., Pinton P., and Giorgi C. PML at Mitochondria-Associated Membranes Is Critical for the Repression of Auto-phagy and Cancer Development. [2016] Cell Reports (16) 9 : 2415-2427.

230. Mittal D., Caramia F., Michiels S., Joensuu H., Kellokumpu-Lehtinen P.L., Sotiriou C., Loi S., and Smyth M.J. Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Si-gnaling in CD8(+) T Cells. [2016] Cancer Research (76) 2 : 264-274.

231. Moehler M., Delic M., Goepfert K., Aust D., Grabsch H.I., Halama N., Heinrich B., Julie C., Lordick F., Lutz M.P., Mauer M., Alsina Maqueda M., Schild H., Schimanski C.C., Wagner A.D., Roth A., and Ducreux M. Immunotherapy in gastrointes-tinal cancer: Recent results, current studies and future perspectives. [2016] European Journal of Cancer (59) : 160-170.

232. Molina-Montes E., Sanchez M.J., Zamora-Ros R., Bueno-De-Mesquita H.B., Wark P.A., Obon-San-tacana M., Kuhn T., Katzke V., Travis R.C., Ye W., Sund M., Naccarati A., Mattiello A., Krogh V., Mar-torana C., Masala G., Amiano P., Huerta J.M., Bar-ricarte A., Quiros J.R., Weiderpass E., Angell Asli

L., Skeie G., Ericson U., Sonestedt E., Peeters P.H., Romieu I., Scalbert A., Overvad K., Clemens M., Boeing H., Trichopoulou A., Peppa E., Vidalis P., Khaw K.T., Wareham N., Olsen A., Tjonneland A., Boutron-Ruault M.C., Clavel-Chapelon F., Cross A.J., Lu Y., Riboli E., and Duell E.J. Flavonoid and lignan intake and pancreatic cancer risk in the Euro-pean prospective investigation into cancer and nutri-tion cohort. [2016] International Journal of Cancer (139) 7 : 1480-1492.

233. Mondragon L., Kroemer G., and Galluzzi L. Immunosuppressive yd T cells foster pancreatic car-cinogenesis. [2016] Oncoimmunology (5) 11 : e1237328.

234. Moskal A., Freisling H., Byrnes G., Assi N., Fahey M.T., Jenab M., Ferrari P., Tjonneland A., Pe-tersen K.E., Dahm C.C., Hansen C.P., Affret A., Bou-tron-Ruault M.C., Cadeau C., Kuhn T., Katzke V., Iq-bal K., Boeing H., Trichopoulou A., Bamia C., Naska A., Masala G., de Magistris M.S., Sieri S., Tumino R., Sacerdote C., Peeters P.H., Bueno-de-Mesqui-ta B.H., Engeset D., Licaj I., Skeie G., Ardanaz E., Buckland G., Castano J.M., Quiros J.R., Amiano P., Molina-Portillo E., Winkvist A., Myte R., Ericson U., Sonestedt E., Perez-Cornago A., Wareham N., Khaw K.T., Huybrechts I., Tsilidis K.K., Ward H., Gunter M.J., and Slimani N. Main nutrient patterns and colorectal cancer risk in the European Prospec-tive Investigation into Cancer and Nutrition study. [2016] British Journal of Cancer (115) 11 : 1430-1440.

235. Mouna L., Hernandez E., Bonte D., Brost R., Amazit L., Delgui L.R., Brune W., Geballe A.P., Beau I., and Esclatine A. Analysis of the role of autophagy inhibition by two complementary human cytomega-lovirus BECN1/Beclin 1-binding proteins. [2016] Au-tophagy (12) 2 : 327-342.

236. Muller D.C., Murphy N., Johansson M., Ferra-ri P., Tsilidis K.K., Boutron-Ruault M.C., Clavel F., Dartois L., Li K., Kaaks R., Weikert C., Bergmann M., Boeing H., Tjonneland A., Overvad K., Redondo M.L., Agudo A., Molina-Portillo E., Altzibar J.M., Ci-rera L., Ardanaz E., Khaw K.T., Wareham N.J., Key T.J., Travis R.C., Bamia C., Orfanos P., Trichopoulou A., Palli D., Pala V., Tumino R., Vineis P., Panico S., Bueno-De-Mesquita H.B., Verschuren W.M., Struijk E.A., Peeters P.H., Engstrom G., Melander O., Sund M., Weiderpass E., Skeie G., Lund E., Norat T., Gun-ter M., Riboli E., and Brennan P. Modifiable causes of premature death in middle-age in Western Europe: results from the EPIC cohort study. [2016] Bmc Medi-cine (14) 1 : 87.

237. Musinova Y.R., Sheval E.V., Dib C., Germini D., and Vassetzky Y.S. Functional roles of HIV-1 Tat protein in the nucleus. [2016] Cellular and Molecular Life Sciences (73) 3 : 589-601.

238. Nagarajan S., Pioche-Durieu C., Tizei L.H., Fang C.Y., Bertrand J.R., Le cam E., Chang H.C., Treussart F., and Kociak M. Simultaneous cathodo-luminescence and electron microscopy cytometry of cellular vesicles labeled with fluorescent nanodia-monds. [2016] Nanoscale (8) 22 : 11588-11594.

239. Nault J.C., Mami I., La Bella T., Datta S., Im-beaud S., Franconi A., Mallet M., Couchy G., Letouze E., Pilati C., Verret B., Blanc J.F., Balabaud C., Cal-deraro J., Laurent A., Letexier M., Bioulac-Sage P., Calvo F., and Zucman-Rossi J. Wild-type AAV Inser-tions in Hepatocellular Carcinoma Do Not Inform De-bate Over Genotoxicity Risk of Vectorized AAV. [2016] Molecular Therapy (24) 4 : 659-660.

240. Navarrete-Munoz E.M., Wark P.A., Romague-ra D., Bhoo-Pathy N., Michaud D., Molina-Montes E., Tjonneland A., Olsen A., Overvad K., Bou-tron-Ruault M.C., Clavel-Chapelon F., Fagherazzi G., Katzke V.A., Kuhn T., Steffen A., Trichopoulou A., Klinaki E., Papatesta E.M., Masala G., Krogh V., Tumino R., Naccarati A., Mattiello A., Peeters P.H., Rylander C., Parr C.L., Skeie G., Weiderpass E., Quiros J.R., Duell E.J., Dorronsoro M., Huerta J.M., Ardanaz E., Wareham N., Khaw K.T., Travis R.C., Key T., Stepien M., Freisling H., Riboli E., and Bue-no-De-Mesquita H.B. Sweet-beverage consump-tion and risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition

(EPIC). [2016] American Journal of Clinical Nutrition (104) 3 : 760-768.

241. Nguyen T.V., Pawlikowska P., Firlej V., Ros-selli F., and Aoufouchi S. V(D)J recombination process and the Pre-B to immature B-cells tran-sition are altered in Fanca-/- mice. [2016] Scientific Reports (6) : 36906.

242. Noman M.Z., Janji B., Berchem G., and Chouaib S. miR-210 and hypoxic microvesicles: Two critical components of hypoxia involved in the regulation of killer cells function. [2016] Cancer Letters (380) 1 : 257-262.

243. Obon-Santacana M., Freisling H., Peeters P.H., Lujan-Barroso L., Ferrari P., Boutron-Ruault M.C., Mesrine S., Baglietto L., Turzanski-Fortner R., Katzke V.A., Boeing H., Quiros J., Molina-Portillo E., Larranaga N., Chirlaque M.D., Barricarte A., Khaw K.T., Wareham N., Travis R.C., Merritt M.A., Gunter M.J., Trichopoulou A., Lagiou P., Naska A., Palli D., Sieri S., Tumino R., Fiano V., Galassom R., Bueno-de-Mesquita H., Onland-Moret N., Idahl A., Lundin E., Weiderpass E., Vesper H., Riboli E., and Duell E.J. Acrylamide and glycidamide hemoglobin adduct levels and endometrial cancer risk: A nested case-control study in nonsmoking postmenopausal women from the EPIC cohort. [2016] International Journal of Cancer (138) 5 : 1129-1138. 244. Olaussen K.A. and Postel-Vinay S. Predictors of chemotherapy efficacy in Non-Small Cell Lung Cancer : a challenging landscape. [2016] Annals of Oncology (27) 11 : 2004-2016.

245. Oude Ophuis C.M., van Akkooi A.C., Rutkows-ki P., Voit C.A., Stepniak J., Erler N.S., Eggermont A.M., Wouters M.W., Grunhagen D.J., and Verhoef C.K. Effects of time interval between primary me-lanoma excision and sentinel node biopsy on positi-vity rate and survival. [2016] European Journal of Can-cer (67) : 164-173.

246. Palazzo A., Bluteau O., Messaoudi K., Maran-goni F., Chang Y., Souquere S., Pierron G., Lapierre V., Zheng Y., Vainchenker W., Raslova H., and De-bili N. The cell division control protein 42 /Src family kinase/Neural Wiskott-Aldrich syndrome protein pathway regulates human proplatelet formation. [2016] Journal of Thrombosis and Haemostasis (14) 12 : 2524-2535.

247. Patrikidou A., Domont J., Chabaud S., Ray-Co-quard I., Coindre J.M., Bui-Nguyen B., Adenis A., Rios M., Bertucci F., Duffaud F., Chevreau C., Cupis-sol D., Perol D., Emile J.F., Blay J.Y., and Le Cesne A. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group. [2016] European Journal of Cancer (52) : 173-180.

248. Pearson A.D., Federico S.M., Aerts I., Hargrave D.R., Dubois S.G., Iannone R., Geschwindt R.D., Wang R., Haluska F.G., Trippett T.M., and Geoerger B. A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors. [2016] Oncotar-get (7) 51 : 84736-84747.

249. Pearson A.D., Herold R., Rousseau R., Copland C., Bradley-Garelik B., Binner D., Capdeville R., Ca-ron H., Carleer J., Chesler L., Geoerger B., Kearns P., Marshall L.V., Pfister S.M., Schleiermacher G., Skolnik J., Spadoni C., Sterba J., van den Berg H., Uttenreuther-Fischer M., Witt O., Norga K., and Vassal G. Implementation of mechanism of action biology-driven early drug development for children with cancer. [2016] European Journal of Cancer (62) : 124-131.

250. Penel N., Coindre J.M., Bonvalot S., Italiano A., Neuville A., Le Cesne A., Terrier P., Ray-Coquard I., Ranchere-Vince D., Robin Y.M., Isambert N., Ferron G., Duffaud F., Bertucci F., Rios M., Stoeckle E., Le Pechoux C., Guillemet C., Courreges J.B., and Blay J.Y. Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. [2016] European Journal of Cancer (58) : 90-96.

251. Pietrocola F., Pol J., Vacchelli E., Baracco E.E., Levesque S., Castoldi F., Chiara M.M., Madeo F., and Kroemer G. Autophagy induction for the treatment of cancer. [2016] Autophagy (12) 10 : 1962-1964. 252. Pitt J.M., Vetizou M., Waldschmitt N., Kroe-mer G., Chamaillard M., Boneca I.G., and Zitvogel L. Fine-tuning cancer immunotherapy: Optimizing the gut microbiome. [2016] Cancer Research (76) 16 : 4602-4607.

253. Pitt J.M., Marabelle A., Eggermont A., Soria J.C., Kroemer G., and Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunothe-rapy. [2016] Annals of Oncology (27) 8 : 1482-1492.

254. Podmore C., Meidtner K., Schulze M.B., Scott R.A., Ramond A., Butterworth A.S., Di Angelantonio E., Danesh J., Arriola L., Barricarte A., Boeing H., Clavel-Chapelon F., Cross A.J., Dahm C.C., Faghe-razzi G., Franks P.W., Gavrila D., Grioni S., Gunter M.J., Gusto G., Jakszyn P., Katzke V., Key T.J., Kuhn T., Mattiello A., Nilsson P.M., Olsen A., Overvad K., Palli D., Quiros J.R., Rolandsson O., Sacerdote C., Sanchez-Cantalejo E., Slimani N., Sluijs I., Spijker-man A.M., Tjonneland A., Tumino R., van d.A., Van Der Schouw Y.T., Feskens E.J., Forouhi N.G., Sharp S.J., Riboli E., Langenberg C., and Wareham N.J. Association of Multiple Biomarkers of Iron Metabo-lism and Type 2 Diabetes: The EPIC-InterAct Study. [2016] Diabetes Care (39) 4 : 572-581.

255. Pol J., Kroemer G., and Galluzzi L. First onco-lytic virus approved for melanoma immunotherapy. [2016] Oncoimmunology (5) 1 : e1115641. 256. Pol J., Buque A., Aranda F., Bloy N., Cremer I., Eggermont A., Erbs P., Fucikova J., Galon J., Lima-cher J.M., Preville X., Sautes-Fridman C., Spisek R., Zitvogel L., Kroemer G., and Galluzzi L. Trial Watch - Oncolytic viruses and cancer therapy. [2016] Oncoimmunology (5) 2 : e1117740.

257. Postel-Vinay S., Aspeslagh S., Lanoy E., Ro-bert C., Soria J., and Marabelle A. Challenges of phase 1 clinical trials evaluating immune check-point-targeted antibodies. [2016] Annals of Oncology (27) 2 : 214-224. 258. Postel-Vinay S., Boursin Y., Massard C., Holle-becque A., Ileana E., Chiron M., Jung J., Lee J., Ba-logh Z., Adam J., Vielh P., Angevin E., Lacroix L., and Soria J. Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing? [2016] Annals of Oncology (27) 2 : 344-352.

259. Pouessel D., Neuzillet Y., Mertens L.S., Van Der Heijden M.S., de Jong J., Sanders J., Peters D., Leroy K., Manceau A., Maille P., Soyeux P., Moktefi A., Semprez F., Vordos D., de la Taille A., Hurst C.D., Tomlinson D.C., Harnden P., Bostrom P.J., Mirtti T., Horenblas S., Loriot Y., Houede N., Chevreau C., Beuzeboc P., Shariat S.F., Sagalowsky A.I., Ashfaq R., Burger M., Jewett M.A., Zlotta A.R., Broeks A., Bapat B., Knowles M.A., Lotan Y., van der Kwast T.H., Culine S., Allory Y., and van Rhijn B.W. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: impli-cations for perioperative anti-FGFR3 treatment. [2016] Annals of Oncology (27) 7 : 1311-1316.

260. Pouessel D., Chevret S., Rolland F., Gravis G., Geoffrois L., Roubaud G., Terrisse S., Boyle H., Chevreau C., Dauba J., Moriceau G., Alexandre I., Deplanque G., Chapelle A., Vauleon E., Colau A., Audenet F., Grellety T., and Culine S. Standard or ac-celerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally ad-vanced urothelial bladder cancer: Does dose intensity matter? [2016] European Journal of Cancer (54) : 69-74.

261. Proudhon C., Snetkova V., Raviram R., Lobry C., Badri S., Jiang T., Hao B., Trimarchi T., Kluger Y., Aifantis I., Bonneau R., and Skok J.A. Active and Inactive Enhancers Cooperate to Exert Localized and Long-Range Control of Gene Regulation. [2016] Cell Reports (15) 10 : 2159-2169.

262. Quinet A., Martins D.J., Vessoni A.T., Biard D., Sarasin A., Stary A., and Menck C.F. Translesion synthesis mechanisms depend on the nature of DNA damage in UV-irradiated human cells. [2016] Nucleic Acids Research (44) 12 : 5717-5131.

263. Rajan A., Berns A., Ringborg U., Celis J., Pon-der B., Caldas C., Livingston D., Bristow R.G., Hecht T.T., Tursz T., van Luenen H., Bono P., Helander T., Seamon K., Smyth J.F., Louvard D., Eggermont A., and van Harten W.H. Excellent translational re-search in oncology: A journey towards novel and more effective anti-cancer therapies. [2016] Molecu-lar Oncology (10) 5 : 645-651.

264. Rambow F., Bechadergue A., Luciani F., Gros G., Domingues M., Bonaventure J., Meurice G., Marine J.C., and Larue L. Regulation of Melanoma Progression through the TCF4/miR-125b/NEDD9 Cascade. [2016] Journal of Investigative Dermatology (136) 6 : 1229-1237.

265. Rancoule C., Magne N., Vallard A., Guy J.B., Rodriguez-Lafrasse C., Deutsch E., and Chargari C. Nanoparticles in radiation oncology: From bench-side to bedside. [2016] Cancer Letters (375) 2 : 256-262 .

266. Raslova H., Vainchenker W., and Plo I. Eltrom-bopag, a potent stimulator of megakaryopoiesis. [2016] Haematologica (101) 12 : 1443-1445. 267. Raut C.P., Miceli R., Strauss D.C., Swallow C.J., Hohenberger P., van Coevorden F., Rutkows-ki P., Fiore M., Callegaro D., Casali P.G., Haas R.L., Hayes A.J., Honore C., Cannell A.J., Jakob J., Szacht M., Fairweather M., Pollock R.E., Bonvalot S., and Gronchi A. External validation of a multi-institutional retroperitoneal sarcoma nomogram. [2016] Cancer (122) 9 : 1417-1424.

268. Redelsperger F., Raddi N., Bacquin A., Verno-chet C., Mariot V., Gache V., Blanchard-Gutton N., Charrin S., Tiret L., Dumonceaux J., Dupressoir A., and Heidmann T. Genetic Evidence That Captured Retroviral Envelope syncytins Contribute to Myoblast Fusion and Muscle Sexual Dimorphism in Mice. [2016] PLoS Genetics (12) 9 : e1006289.

269. Remon J., Lindsay C.R., Bluthgen M.V., and Besse B. Thymic malignancies: Moving forward with new systemic treatments. [2016] Cancer Treatment Reviews (46) : 27-34. 270. Remon J., Bonastre J., and Besse B. The 5000% case: a glimpse into the financial issue of lung cancer treatment. [2016] European Respiratory Journal (47) 5 : 1331-1333.

271. Renaud E., Barascu A., and Rosselli F. Impaired TIP60-mediated H4K16 acetylation accounts for the aberrant chromatin accumulation of 53BP1 and RAP80 in Fanconi anemia pathway-deficient cells. [2016] Nucleic Acids Research (44) 2 : 648-656.

272. Renaudin X., Koch L.L., Menck C.F., and Ros-selli F. The ubiquitin family meets the Fanconi ane-mia proteins. [2016] Mutation Research - Reviews in Mutation Research (769) : 36-46.

273. Rigaud C., Barkaoui M.A., Thomas C., Bertrand Y., Lambilliotte A., Miron J., Aladjidi N., Plat G., Je-ziorski E., Galambrun C., Mansuy L., Lutz P., Deville A., Armari-Alla C., Reguerre Y., Fraitag S., Cou-lomb A., Gandemer V., Leboulanger N., Moshous D., Hoang-Xuan K., Tazi A., Heritier S., Emile J.F., and Donadieu J. Langerhans cell histiocytosis: thera-peutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. [2016] British Journal of Haematology (174) 5 : 887-898.

274. Rios P., Bailey H.D., Orsi L., Lacour B., Val-teau-Couanet D., Levy D., Corradini N., Leverger G., Defachelles A.S., Gambart M., Sirvent N., Thebaud E., Ducassou S., and Clavel J. Risk of neuroblasto-ma, birth-related characteristics, congenital malfor-mations and perinatal exposures: A pooled analysis of the ESCALE and ESTELLE French studies (SFCE). [2016] International Journal of Cancer (139) 9 : 1936-1948.

275. Rivoirard R., Vallard A., Langrand-Escure J., Ben Mrad M., Wang G., Guy J.B., Diao P., Dubanchet A., Deutsch E., Rancoule C., and Magne N. Thirty years of phase i radiochemotherapy trials: Latest de-velopment. [2016] European Journal of Cancer (58) : 1-7.

276. Rivoisy C., Besse B., Girard N., Lioger B., Vial-lard J.F., Lega J.C., Rullier P., Pertat A., Lerouge D., Clement-Duchene C., Ebbo M., Bosseray A., Godeau B., and Lambotte O. Thymic Epithelial Tumor-Asso-ciated Cytopenia: A 10-Year Observational Study in France. [2016] Journal of Thoracic Oncology (11) 3 : 391-399.

277. Robinson B., Schlumberger M., Wirth L.J., Dutcus C.E., Song J., Taylor M.H., Kim S.B., Krzy-zanowska M.K., Capdevila J., Sherman S.I., and Tahara M. Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. [2016] Journal of Clinical Endocrinolo-gy & Metabolism (101) 11 : 4103-4109.

278. Rodriguez C., Suciu V., Poterie A., Lacroix L., Miran I., Boichard A., Delaloge S., Deneuve J., Azou-lay S., Mathieu M.C., Valent A., Michiels S., Arnedos M., and Vielh P. Concordance between HER-2 status determined by qPCR in Fine Needle Aspiration Cyto-logy (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients. [2016] Molecular Oncology (10) 9 : 1430-1436.

279. Roos-Weil D., Nguyen-Khac F., and Bernard O.A. Chronic lymphocytic leukemia: Time to go past genomics? [2016] American Journal of Hematology (91) 5 : 518-528.

280. Rouanne M., Loriot Y., Lebret T., and Soria J.C. Novel therapeutic targets in advanced urothelial car-cinoma. [2016] Critical Reviews in Oncology/Hematolo-gy (98) : 106-115.

281. Roy A., Lordier L., Pioche-Durieu C., Souquere S., Roy L., Rameau P., Lapierre V., Le cam E., Plo I., Debili N., Raslova H., and Vainchenker W. Uncou-pling of the Hippo and Rho pathways allows megaka-ryocytes to escape the tetraploid checkpoint. [2016] Haematologica (101) 12 : 1469-1478.

282. Saintigny Y., Chevalier F., Bravard A., Dardillac E., Laurent D., Hem S., Depagne J., Radicella J.P., and Lopez B.S. A threshold of endogenous stress is required to engage cellular response to protect against mutagenesis. [2016] Scientific Reports (6) : 29412.

283. Sarkozy C., Molina T., Ghesquieres H., Michal-let A.S., Dupuis J., Damotte D., Morsschauser F., Parrens M., Martin L., Dartigues P., Stamatoullas A., Hirsch P., Fabiani B., Bouabdallah K., da Silva M.G., Maerevoet M., Laurent C., Coiffier B., Salles G., and Traverse-Glehen A. Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. [2016] Haematologica (102) 1 : 150-159.

284. Scelo G., Hofmann J.N., Banks R.E., Bigot P., Bhatt R.S., Cancel-Tassin G., Chew S.K., Creighton C.J., Cussenot O., Davis I.J., Escudier B., Frayling T.M., Haggstrom C., Hildebrandt M.A., Holcatova I., Johansson M., Linehan W.M., McDermott D.F., Na-thanson K.L., Ogawa S., Perlman E.J., Purdue M.P., Stattin P., Swanton C., Vasudev N.S., Wu X., Znaor A., Brennan P., and Chanock S.J. International can-cer seminars: a focus on kidney cancer. [2016] Annals of Oncology (27) 8 : 1382-1385.

285. Schadendorf D., Dummer R., Hauschild A., Robert C., Hamid O., Daud A., van den Eertwegh A., Cranmer L., O’Day S., Puzanov I., Schachter J., Blank C., Salama A., Loquai C., Mehnert J.M., Hille D., Ebbinghaus S., Kang S.P., Zhou W., and Ribas A. Health-related quality of life in the randomised KEY-NOTE-002 study of pembrolizumab versus chemo-therapy in patients with ipilimumab-refractory me-lanoma. [2016] European Journal of Cancer (67) : 46-54.

286. Schlumberger M., Jarzab B., Cabanillas M.E., Robinson B., Pacini F., Ball D.W., McCaffrey J., Newbold K., Allison R., Martins R.G., Licitra L.F., Shah M.H., Bodenner D., Elisei R., Burmeister L., Funahashi Y., Ren M., O’Brien J.P., and Sherman S.I.

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. [2016] Clinical Cancer Research (22) 1 : 44-53.

287. Schuler M., Yang J.C.H., Park K., Kim J.H., Bennouna J., Chen Y.M., Chouaid C., De Marinis F., Feng J.F., Grossi F., Kim D.W., Liu X., Lu S., Strausz J., Vinnyk Y., Wiewrodt R., Zhou C., Wang B., Chand V.K., Planchard D., Bagnes C., Martin C.M., Recondo G., Zarba J.J., Blajman C., Richar-det M., McLachlan S.A., Parente P., Underhill C., Crombie C., Mainwaring P., Greil R., Humblet Y., Bustin F., Carestia L., Galdermans D., Lambre-chts M., Delval L., Vercauter P., Zhou C., Wang J., Huang C., Lin X., Wu Y., Liu X., Cheng Y., Qin S., Feng J., Huang J., Zhang Y., Lu S., Zereu M., Garicochea B., Zadra C.A., Riska H., Alanko T., Cadranel J., Chouaid C., Zalcman G., Sibilot D.M., Perol M., Planchard D., Bennouna J., Fournel P., Gervais R., Rotarski M., Coudert B., Thomas M., Wehler T., Faehling M., Keilholz U., Laack E., Von Pawel J., Huber R., Dickgreber N., Wiewro-dt R., Mark Z., Tehenes S., Strausz J., Sarosi V., Prabhash K., Jain M., Venkatesan S., Sharma L., Dadhich H., Nagarkar R.V., Onn A., Gottfried M., Stemmer S., Migliorino M.R., Grossi F., Bidoli P., Bearz A., Gridelli C., Milandri C., Platania M., Ceresoli G.L., Cruciani G., Delgado F.G., Perez J.L.G., Luna G.A., Baca O.P., Aerts J., Stigt J., Din-gemans A.M., Herder G., Gans S., Sanchez J.F.S., Barreda R.L.A., Pantigoso W.R., Palomino O.L.M., Jaskiewicz P., Kazarnowicz A., Serwatowski P., Szczesna A., Jassem J., Lubennikov V., Karaseva N., Orlov S., Ragulin Y., Garrido P., Larriba J.L.G., Camps C., Campelo R.G., Lianes P., Cobo M., Fe-lip E., Kim D.W., Kim S.W., Park K., Kim J.H., Han J.Y., Kim Y.C., Yang C.H., Hsia T.C., Chen Y.M., Tsai Y.H., Chang G.C., Tsao T.C.Y., Su W.C., Huang M.S., Ho C.L., Hsieh R.K., Vinnyk Y., Popovych O., Po-nomarova O., Bondarenko I., Polishchuk I., Shah R., Mitra S., Popat S., Spicer J., Toy E., Talbot T., Brown E., Upadhyay S., Summers Y., Gurtler J., Meza L., and Thropay J. Afatinib beyond progres-sion in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial. [2016] Annals of Oncology (27) 3 : 417-423.

288. Schuler M., Yang J.C., and Planchard D. Reply to the letter to the editor ‘What is the clinical impact of the LUX-Lung 5 trial?’ by Addeo. [2016] Annals of Oncology (27) 6 : 1172-1173.

289. Semeraro M., Adam J., Stoll G., Louvet E., Chaba K., Poirier-Colame V., Sauvat A., Senovilla L., Vacchelli E., Bloy N., Humeau J., Buque A., Kepp O., Zitvogel L., Andre F., Mathieu M.C., Delaloge S., and Kroemer G. The ratio of CD8+/FOXP3 T lympho-cytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ. [2016] Oncoimmunology (5) 10 : e1218106.

290. Sherman S.I., Clary D.O., Elisei R., Schlum-berger M.J., Cohen E.E., Schoffski P., Wirth L.J., Mangeshkar M., Aftab D.T., and Brose M.S. Corre-lative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. [2016] Cancer (122) 24 : 3856-3864.

291. Sibon D., Morschhauser F., Resche-Rigon M., Ghez D., Dupuis J., Marçais A., Deau-Fischer B., Bouabdallah R., Sebban C., Salles G., and Brice P. Single or tandem autologous stem-cell transplanta-tion for first-relapsed or refractory Hodgkin lympho-ma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. [2016] Haematologi-ca (101) 4 : 474-481.

292. Silve A., Leray I., Poignard C., and Mir L.M. Im-pact of external medium conductivity on cell membrane electropermeabilization by microsecond and nanose-cond electric pulses. [2016] Scientific Reports (6) : 19957.

293. Singhal S.K., Usmani N., Michiels S., Metz-ger-Filho O., Saini K.S., Kovalchuk O., and Parlia-ment M. Towards understanding the breast cancer epigenome: a comparison of genome-wide DNA methylation and gene expression data. [2016] Onco-target (7) 3 : 3002-3017.

294. Sitbon P., Van Elstraete A., Hamdi L., Jua-rez-Perez V., Mazoit J.X., Benhamou D., and Rou-geot C. STR-324, a Stable Analog of Opiorphin, Causes Analgesia in Postoperative Pain by Activating Endogenous Opioid Receptor-dependent Pathways. [2016] Anesthesiology (125) 5 : 1017-1029.

295. Socoro-Yuste N., Dagher M.C., Gonzalez De P.A., Mondet J., Zaccaria A., Roux D.F., Plo I., Cahn J.Y., and Mossuz P. Ph- myeloproliferative neoplasm red blood cells display deregulation of IQGAP1-Rho GTPase signaling depending on CALR/JAK2 status. [2016] Biochimica et Biophysica Acta - Molecular Cell Research (1863) 11 : 2758-2765. 296. Solary E. Unplugging JAK/STAT in Chronic Myelomonocytic Leukemia. [2016] Clinical Cancer Re-search (22) 15 : 3707-3709.

297. Solomon B. and Soria J.C. The continuum of care for ALK-positive NSCLC: from diagnosis to new treatment options - an overview. [2016] Annals of On-cology (27) suppl 3 : iii1-iii3.

298. Soria J.C., Gan H.K., Blagden S.P., Plummer R., Arkenau H.T., Ranson M., Evans T.R., Zalcman G., Bahleda R., Hollebecque A., Lemech C., Dean E., Brown J., Gibson D., Peddareddigari V., Murray S., Nebot N., Mazumdar J., Swartz L., Auger K.R., Fleming R.A., Singh R., and Millward M. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. [2016] Annals of Oncology (27) 12 : 2268-2274. 299. Soria J.C. Annals of oncology in 2015: the year in review. [2016] Annals of Oncology (27) 1 : 8-9.

300. Soria J.C. New goals. [2016] Annals of Oncology (27) 9 : 1655-1656.

301. Stepien M., Duarte-Salles T., Fedirko V., Floegel A., Barupal D.K., Rinaldi S., Achaintre D., Assi N., Tjonneland A., Overvad K., Bastide N., Boutron-Ruault M.C., Severi G., Kuehn T., Kaaks R., Aleksandrova K., Boeing H., Trichopoulou A., Bamia C., Lagiou P., Saieva C., Agnoli C., Panico S., Tumino R., Naccarati A., Bueno-de-Mesquita H., Peeters P.H., Weiderpass E., Ramon Quiros J., Agudo A., Sanchez M.J., Dorronsoro M., Gavrila D., Barricarte A., Ohlsson B., Sjoberg K., Werner M., Sund M., Wareham N., Khaw K.T., Travis R.C., Sch-midt J.A., Gunter M., Cross A., Vineis P., Romieu I., Scalbert A., and Jenab M. Alteration of amino acid and biogenic amine metabolism in hepatobiliary can-cers: Findings from a prospective cohort study. [2016] International Journal of Cancer (138) 2 : 348-360. 302. Stoll G., Iribarren K., Michels J., Leary A., Zitvo-gel L., Cremer I., and Kroemer G. Calreticulin expres-sion: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer. [2016] Oncoimmunology (5) 7 : e1177692.

303. Stoll G., Zitvogel L., and Kroemer G. Diffe-rences in the composition of the immune infiltrate in breast cancer, colorectal carcinoma, melanoma and non-small cell lung cancer: A microarray-based me-ta-analysis. [2016] Oncoimmunology (5) 2 : e1067746.

304. Swanton C., Soria J.C., Bardelli A., Biankin A., Caldas C., Chandarlapaty S., de Koning L., Dive C., Feunteun J., Leung S.Y., Marais R., Mardis E.R., McGranahan N., Middleton G., Quezada S.A., Rodon J., Rosenfeld N., Sotiriou C., and Andre F. Consen-sus on precision medicine for metastatic cancers: a report from the MAP conference. [2016] Annals of Oncology (27) 8 : 1443-1448.

305. Swanton C., Boffetta P., Peston R., and Soria J.C. Environmental emissions, public health and lung cancer risk. [2016] Annals of Oncology (27) 2 : 211-212.

306. Swanton C., Boffetta P., Peston R., and Soria J.C. Reply to the letter to the editor ‘Abandoning die-sel because of health perspectives: are there reaso-nable alternatives?’ by Vreugdenhil and Mannaerts. [2016] Annals of Oncology (27) 7 : 1361.

307. Tacher V., Le Deley M.C., Hollebecque A., Des-champs F., Vielh P., Hakime A., Ileana E., Abedi-Ar-dekani B., Charpy C., Massard C., Rosellini S., Gajda D., Celebic A., Ferte C., Ngo-Camus M., Gouissem S., Koubi-Pick V., Andre F., Vassal G., Deandreis D., Lacroix L., Soria J.C., and de Baere T. Factors as-sociated with success of image-guided tumour biop-sies: Results from a prospective molecular triage study (MOSCATO-01). [2016] European Journal of Can-cer (59) : 79-89.

308. Talhaoui I., Lebedeva N.A., Zarkovic G., Saint-Pierre C., Kutuzov M.M., Sukhanova M.V., Matka-rimov B.T., Gasparutto D., Saparbaev M.K., Lavrik O.I., and Ishchenko A.A. Poly(ADP-ribose) polyme-rases covalently modify strand break termini in DNA fragments in vitro. [2016] Nucleic Acids Research (44) 19 : 9279-9295. 309. Taty-Taty G.C., Chailleux C., Quaranta M., So A., Guirouilh-Barbat J., Lopez B.S., Bertrand P., Trouche D., and Canitrot Y. Control of alternative end joining by the chromatin remodeler p400 ATPase. [2016] Nucleic Acids Research (44) 4 : 1657-1668.

310. Taylor N.J., Handorf E.A., Mitra N., Avril M.F., Azizi E., Bergman W., Bianchi-Scarra G., Bi-shop D., Bressac-de Paillerets B., Calista D., Can-non-Albright L.A., Cuellar F., Cust A.E., Demenais F., Elder D.E., Friedman E., Gerdes A.M., Ghiorzo P., Goldstein A.M., Grazziotin T.C., Hansson J., Hayward N.K., Hocevar M., Hoiom V., Holland E.A., Ingvar C., Landi M.T., Landman G., Larre-Borges A., Leachman S.A., Mann G.J., Nagore E., Olsson H., Palmer J., Peric B., Pjanova D., Puig S., Schmid H., van der Stoep N., Tucker M.A., Wadt K.A., Whitaker L., Yang X.R., Bishop J.A., Gruis N.A., and Kanetsky P.A. Phenotypic and Histopathological Tumor Cha-racteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families. [2016] Journal of Investigative Dermatology (136) 5 : 1066-1069.

311. Techer H., Koundrioukoff S., Carignon S., Wil-helm T., Millot G.A., Lopez B.S., Brison O., and De-batisse M. Signaling from Mus81-Eme2-Dependent DNA Damage Elicited by Chk1 Deficiency Modulates Replication Fork Speed and Origin Usage. [2016] Cell Reports (14) 5 : 1114-1127. 312. Terry K.L., Schock H., Fortner R.T., Husing A., Fichorova R.N., Yamamoto H.S., Vitonis A.F., John-son T., Overvad K., Tjonneland A., Boutron-Ruault M.C., Mesrine S., Severi G., Dossus L., Rinaldi S., Boeing H., Benetou V., Lagiou P., Trichopoulou A., Krogh V., Kuhn E., Panico S., Bueno-De-Mesquita H.B., Onland-Moret N.C., Peeters P.H., Gram I.T., Weiderpass E., Duell E.J., Sanchez M.J., Ardanaz E., Etxezarreta N., Navarro C., Idahl A., Lundin E., Jirstrom K., Manjer J., Wareham N.J., Khaw K.T., Byrne K.S., Travis R.C., Gunter M.J., Merritt M.A., Riboli E., Cramer D.W., and Kaaks R. A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort. [2016] Clinical Cancer Research (22) 18 : 4664-4675.

313. Thebault S., Agez M., Chi X., Stojko J., Cura V., Telerman S.B., Maillet L., Gautier F., Billas-Mas-sobrio I., Birck C., Troffer-Charlier N., Karafin T., Honore J., Senff-Ribeiro A., Montessuit S., Johnson C.M., Juin P., Cianferani S., Martinou J.C., Andrews D.W., Amson R., Telerman A., and Cavarelli J. TCTP contains a BH3-like domain, which instead of inhi-biting, activates Bcl-xL. [2016] Scientific Reports (6) : 19725.

314. Thouvenot P., Ben Y.B., Fourriere L., Lescure A., Boudier T., Del N.E., Chauchereau A., Goldgar D.E., Houdayer C., Stoppa-Lyonnet D., Nicolas A., and Millot G.A. Functional Assessment of Genetic Variants with Outcomes Adapted to Clinical Deci-sion-Making. [2016] PLoS Genetics (12) 6 : e1006096.

315. Thuringer D., Jego G., Berthenet K., Hammann A., Solary E., and Garrido C. Gap junction-mediated transfer of miR-145-5p from microvascular endothe-lial cells to colon cancer cells inhibits angiogenesis. [2016] Oncotarget (7) 19 : 28160-28168.

316. Thuringer D., Boucher J., Jego G., Pernet N., Cronier L., Hammann A., Solary E., and Garrido C. Transfer of functional microRNAs between glioblas-toma and microvascular endothelial cells through gap junctions. [2016] Oncotarget (7) 45 : 73925-73934.

317. Tissot T., Ujvari B., Solary E., Lassus P., Roche B., and Thomas F. Do cell-autonomous and non-cell-autonomous effects drive the structure of tumor ecosystems? [2016] Biochimica et Biophysica Acta - Reviews on Cancer (1865) 2 : 147-154.

318. Tlemsani C., Mir O., Psimaras D., Vano Y.A., Ducreux M., Escudier B., Rousseau B., Loirat D., Ceccaldi B., Andre T., Goldwasser F., and Ricard D. Acute neurovascular events in cancer patients recei-ving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals. [2016] European Journal of Cancer (66) : 75-82.

319. Tortola L., Nitsch R., Bertrand M.J., Kogler M., Redouane Y., Kozieradzki I., Uribesalgo I., Fen-nell L.M., Daugaard M., Klug H., Wirnsberger G., Wimmer R., Perlot T., Sarao R., Rao S., Hanada T., Takahashi N., Kernbauer E., Demiroz D., Super-ti-Furga G., Decker T., Pichler A., Ikeda F., Kroemer G., Vandenabeele P., Sorensen P.H., and Penninger J.M. The Tumor Suppressor Hace1 Is a Critical Re-gulator of TNFR1-Mediated Cell Fate. [2016] Cell Re-ports (15) 7 : 1481-1492.

320. Tosco A., De Gregorio F., Esposito S., De Ste-fano D., Sana I., Ferrari E., Sepe A., Salvadori L., Buonpensiero P., Di P.A., Grassia R., Leone C.A., Guido S., De Rosa G., Lusa S., Bona G., Stoll G., Maiuri M.C., Mehta A., Kroemer G., Maiuri L., and Raia V. A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mu-tated CFTR. [2016] Cell Death & Differentiation (23) 8 : 1380-1393.

321. Tranchart H., Koffi G.M., Gaillard M., Lainas P., Pous C., Gonin P., Nguyen T.H., Dubart-Kuppersch-mitt A., and Dagher I. Liver regeneration following repeated reversible portal vein embolization in an experimental model. [2016] British Journal of Surgery (103) 9 : 1209-1219. 322. Tromme I., Legrand C., Devleesschauwer B., Leiter U., Suciu S., Eggermont A., Sacre L., Bau-rain J.F., Thomas L., Beutels P., and Speybroeck N. Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy. [2016] Eu-ropean Journal of Cancer (67) : 38-45. 323. Tromme I., Legrand C., Devleesschauwer B., Leiter U., Suciu S., Eggermont A., Francart J., Calay F., Haagsma J.A., Baurain J.F., Thomas L., Beutels P., and Speybroeck N. Melanoma burden by melano-ma stage: Assessment through a disease transition model. [2016] European Journal of Cancer (53) : 33-41. 324. Turner S.D., Lamant L., Kenner L., and Bru-gieres L. Anaplastic large cell lymphoma in paedia-tric and young adult patients. [2016] British Journal of Haematology (173) 4 : 560-572. 325. Ugurel S., Roehmel J., Ascierto P.A., Flaherty K.T., Grob J.J., Hauschild A., Larkin J., Long G.V., Lo-rigan P., McArthur G.A., Ribas A., Robert C., Schaden-dorf D., and Garbe C. Survival of patients with advanced metastatic melanoma: The impact of novel therapies. [2016] European Journal of Cancer (53) : 125-134. 326. Urbinati G., de Waziers I., Slamic M., Foussi-gniere T., Ali H.M., Desmaele D., Couvreur P., and Massaad-Massade L. Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alterna-tive Treatment to Flutamide. [2016] Molecular The-rapy-Nucleic Acids (5) : e301.

327. Vacchelli E., Aranda F., Bloy N., Buqué A., Cre-mer I., Eggermont A., Fridman W.H., Fucikova J., Galon J., Spisek R., Zitvogel L., Kroemer G., and Galluzzi L. Trial Watch - Immunostimulation with cytokines in cancer therapy. [2016] Oncoimmunology (5) 2 : e1115942.

328. Vacchelli E., Bloy N., Aranda F., Buque A., Cre-mer I., Demaria S., Eggermont A., Formenti S.C., Fridman W.H., Fucikova J., Galon J., Spisek R., Tartour E., Zitvogel L., Kroemer G., and Galluzzi L. Trial Watch: Immunotherapy plus radiation therapy for oncological indications. [2016] Oncoimmunology (5) 9 : e1214790. 329. Vacchelli E., Ma Y., Baracco E.E., Zitvogel L., and Kroemer G. Yet another pattern recognition receptor involved in the chemotherapy-induced an-ticancer immune response: Formyl peptide recep-tor-1. [2016] Oncoimmunology (5) 5 : e1118600. 330. Vacchelli E., Semeraro M., Adam J., Dartigues P., Zitvogel L., and Kroemer G. Immunosurveil-lance in esophageal carcinoma: The decisive impact of regulatory T cells. [2016] Oncoimmunology (5) 2 : e1064581. 331. Vacchelli E., Enot D.P., Pietrocola F., Zitvogel L., and Kroemer G. Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Pa-tients Undergoing Adjuvant Chemotherapy. [2016] Cancer Research (76) 11 : 3122-3126.

332. Valentin T., Le Cesne A., Ray-Coquard I., Italia-no A., Decanter G., Bompas E., Isambert N., Thariat J., Linassier C., Bertucci F., Bay J.O., Bellesoeur A., Penel N., Le Guellec S., Filleron T., and Chevreau C. Management and prognosis of malignant peri-pheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO). [2016] Euro-pean Journal of Cancer (56) : 77-84.

333. Van Cutsem E., Cervantes A., Adam R., Sobre-ro A., Van Krieken J.H., Aderka D., Aranda A.E., Bardelli A., Benson A., Bodoky G., Ciardiello F., D’Hoore A., Diaz-Rubio E., Douillard J.Y., Ducreux M., Falcone A., Grothey A., Gruenberger T., Haus-termans K., Heinemann V., Hoff P., Kohne C.H., La-bianca R., Laurent-Puig P., Ma B., Maughan T., Muro K., Normanno N., Osterlund P., Oyen W.J., Papami-chael D., Pentheroudakis G., Pfeiffer P., Price T.J., Punt C., Ricke J., Roth A., Salazar R., Scheithauer W., Schmoll H.J., Tabernero J., Taieb J., Tejpar S., Wasan H., Yoshino T., Zaanan A., and Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. [2016] An-nals of Oncology (27) 8 : 1386-1422. 334. Van Gool I.C., Stelloo E., Nout R.A., Nijman H.W., Edmondson R.J., Church D.N., MacKay H.J., Leary A., Powell M.E., Mileshkin L., Creutzberg C.L., Smit V.T., and Bosse T. Prognostic significance of L1CAM expression and its association with mu-tant p53 expression in high-risk endometrial cancer. [2016] Modern Pathology (29) 2 : 174-181. 335. Vences-Catalan F., Rajapaksa R., Srivastava M.K., Marabelle A., Kuo C.C., Levy R., and Levy S. Tetraspanin CD81, a modulator of immune suppres-sion in cancer and metastasis. [2016] Oncoimmunolo-gy (5) 5 : e1120399.

336. Veyrat M., Durand S., Classe M., Glavan T.M., Oker N., Kapetanakis N.I., Jiang X., Gelin A., Her-man P., Casiraghi O., Zagzag D., Enot D., Busson P., and Verillaud B. Stimulation of the toll-like recep-tor 3 promotes metabolic reprogramming in head and neck carcinoma cells. [2016] Oncotarget (7) 50 : 82580-82593.

337. Vlenterie M., Litiere S., Rizzo E., Marreaud S., Judson I., Gelderblom H., Le Cesne A., Wardel-mann E., Messiou C., Gronchi A., and van der Graaf W.T. Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; set-ting a new landmark for studies in this entity. [2016] European Journal of Cancer (58) : 62-72.

338. Voican C.S., Mir O., Loulergue P., Dhooge M., Brezault C., Dreanic J., Chaussade S., Pol S., and Coriat R. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. [2016] Annals of Oncology (27) 12 : 2172-2184.

339. Wardelmann E., Haas R., Bovee J., V, Terrier P., Lazar A., Messiou C., LePechoux C., Hartmann W., Collin F., Fisher C., Mech-tersheimer G., DeiTos A., Stacchiotti S., Jones R., Gronchi A., and Bonvalot S. Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) re-commendations for pathological examination and reporting. [2016] European Journal of Cancer (53) : 84-95. 340. Wilhelm T., Ragu S., Magdalou I., Machon C., Dardillac E., Techer H., Guitton J., Debatisse M., and Lopez B.S. Slow Replication Fork Velo-city of Homologous Recombination-Defective Cells Results from Endogenous Oxidative Stress. [2016] PLoS Genetics (12) 5 : e1006007. 341. Willekens C., Blanchet O., Renneville A., Cornillet-Lefebvre P., Pautas C., Guieze R., Ifrah N., Dombret H., Jourdan E., Preudhomme C., and Boissel N. Prospective long-term mini-mal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial. [2016] Haematologica (101) : 328-335. 342. Wimmer K., Brugieres L., Duval A., Mule-ris M., Kratz C.P., and Vasen H.F. Constitutional or biallelic? Settling on a name for a recessively inherited cancer susceptibility syndrome. [2016] Journal of Medical Genetics (53) 4 : 226-226. 343. Wiraswati H.L., Hangen E., Sanz A.B., Lam N.V., Reinhardt C., Sauvat A., Mogha A., Ortiz A., Kroemer G., and Modjtahedi N. Apoptosis in-ducing factor (AIF) mediates lethal redox stress induced by menadione. [2016] Oncotarget (7) 47 : 76496-76507. 344. Xie C., Ginet V., Sun Y., Koike M., Zhou K., Li T., Li H., Li Q., Wang X., Uchiyama Y., Trutt-mann A.C., Kroemer G., Puyal J., Blomgren K., and Zhu C. Neuroprotection by selective neu-ronal deletion of Atg7 in neonatal brain injury. [2016] Autophagy (12) 2 : 410-423.

345. Yamazaki T., Pitt J., Vetizou M., Marabelle A., Flores C., Rekdal O., Kroemer G., and Zitvogel L. The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade. [2016] Cell Death & Differentiation (23) 6 : 1004-1015.

346. Yang H., Ma Y., Chen G., Zhou H., Yamazaki T., Klein C., Pietrocola F., Vacchelli E., Souquere S., Sauvat A., Zitvogel L., Kepp O., and Kroemer G. Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. [2016] On-coimmunology (5) 6 : e1149673. 347. Yang H., Yamazaki T., Pietrocola F., Zhou H., Zi-tvogel L., Ma Y., and Kroemer G. Improvement of im-munogenic chemotherapy by STAT3 inhibition. [2016] Oncoimmunology (5) 2 : e1078061. 348. Zamora-Ros R., Achaintre D., Rothwell J.A., Rinaldi S., Assi N., Ferrari P., Leitzmann M., Bou-tron-Ruault M.C., Fagherazzi G., Auffret A., Kuhn T., Katzke V., Boeing H., Trichopoulou A., Naska A., Vasilopoulou E., Palli D., Grioni S., Mattiello A., Tu-mino R., Ricceri F., Slimani N., Romieu I., and Scal-bert A. Urinary excretions of 34 dietary polyphenols and their associations with lifestyle factors in the EPIC cohort study. [2016] Scientific Reports (6) : 26905. 349. Zamora-Ros R., Rinaldi S., Tsilidis K.K., Weider-pass E., Boutron-Ruault M.C., Rostgaard-Hansen A.L., Tjonneland A., Clavel-Chapelon F., Mesrine S., Katzke V.A., Kuehn T., Foerster J., Boeing H., Tri-chopoulou A., Lagiou P., Klinaki E., Masala G., Sieri S., Ricceri F., Tumino R., Mattiello A., Peeters P.H., Bueno-de-Mesquita H., Engeset D., Skeie G., Ar-gueelles M., Agudo A., Sanchez M.J., Chirlaque M.D., Barricarte A., Chamosa S., Almquist M., Tosovic A., Hennings J., Sandstrom M., Schmidt J.A., Khaw K.T., Wareham N.J., Cross A.J., Slimani N., Byrnes G., Romieu I., Riboli E., and Franceschi S. Energy and macronutrient intake and risk of differentiated thyroid carcinoma in the European Prospective Investigation into Cancer and Nutrition study. [2016] International Journal of Cancer (138) 1 : 65-73. 350. Zhang M., Wang Z., Obazee O., Jia J., Childs E.J., Hoskins J., Figlioli G., Mocci E., Collins I., Chung C.C., Hautman C., Arslan A.A., Beane-Free-man L., Bracci P.M., Buring J., Duell E.J., Gallin-ger S., Giles G.G., Goodman G.E., Goodman P.J., Kamineni A., Kolonel L.N., Kulke M.H., Malats N., Olson S.H., Sesso H.D., Visvanathan K., White E., Zheng W., Abnet C.C., Albanes D., Andreotti G., Brais L., Bueno-De-Mesquita H.B., Basso D., Berndt S.I., Boutron-Ruault M.C., Bijlsma M.F., Brenner H., Burdette L., Campa D., Caporaso N.E., Capurso G., Cavestro G.M., Cotterchio M., Costello E., Elena J., Boggi U., Gaziano J.M., Gazouli M., Gio-vannucci E.L., Goggins M., Gross M., Haiman C.A., Hassan M., Helzlsouer K.J., Hu N., Hunter D.J., Iskierka-Jazdzewska E., Jenab M., Kaaks R., Key

T.J., Khaw K.T., Klein E.A., Kogevinas M., Krogh V., Kupcinskas J., Kurtz R.C., Landi M.T., Landi S., Le Marchand L., Mambrini A., Mannisto S., Milne R.L., Neale R.E., Oberg A.L., Panico S., Patel A.V., Pee-ters P.H., Peters U., Pezzilli R., Porta M., Purdue M., Quiros J.R., Riboli E., Rothman N., Scarpa A., Scelo G., Shu X.O., Silverman D.T., Soucek P., Strobel O., Sund M., Malecka-Panas E., Taylor P.R., Ta-vano F., Travis R.C., Thornquist M., Tjonneland A., Tobias G.S., Trichopoulos D., Vashist Y., Vo-dicka P., Wactawski-Wende J., Wentzensen N., Yu H., Yu K., Zeleniuch-Jacquotte A., Kooper-berg C., Risch H.A., Jacobs E.J., Li D., Fuchs C., Hoover R., Hartge P., Chanock S.J., Petersen G.M., Stolzenberg-Solomon R.S., Wolpin B.M., Kraft P., Klein A.P., Canzian F., and Amundadot-tir L.T. Three new pancreatic cancer susceptibi-lity signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. [2016] Oncotarget (7) 41 : 66328 -66343. 351. Zhang Y., Depond M., He L., Foudi A., Kwar-teng E.O., Lauret E., Plo I., Desterke C., Dessen P., Fujii N., Opolon P., Herault O., Solary E., Vainchenker W., Joulin V., Louache F., and Wit-tner M. CXCR4/CXCL12 axis counteracts hema-topoietic stem cell exhaustion through selective protection against oxidative stress. [2016] Scientific Reports (6) : 37827. 352. Zhou H., Sauvat A., Gomes-da-Silva L.C., Durand S., Forveille S., Iribarren K., Yamazaki T., Souquere S., Bezu L., Muller K., Leduc M., Liu P., Zhao L., Marabelle A., Zitvogel L., Rekdal O., Kepp O., and Kroemer G. The oncolytic compound LTX-401 targets the Golgi apparatus. [2016] Cell Death & Differentiation (23) 12 : 2031-2041. 353. Zhou H., Forveille S., Sauvat A., Yamazaki T., Senovilla L., Ma Y., Liu P., Yang H., Bezu L., Mueller K., Zitvogel L., Rekdal O., Kepp O., and Kroemer G. The oncolytic peptide LTX-315 trig-gers immunogenic cell death. [2016] Cell Death & Disease (7) : e2134.